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ABSTRACT 
           Inflammatory bowel diseases (IBD), mainly ulcerative colitis (UC), Crohn’s disease 
(CD), are chronic, idiopathic, inflammatory diseases of the gastrointestinal tract affecting 
millions of people worldwide. The incidence of IBD is steadily increasing in the modern 
world due to changes in dietary habits and other environmental influences that originated 
from industrialization. The etiology is poorly understood but is believed to be a 
combination of genetic predisposition, environmental factors, and overactive immune 
system. UC is characterized by inflammation and ulceration of colonic mucosa and rectum 
and has a higher incidence than CD. Aside from severely affecting the quality of life of the 
patients, IBD also increases the risk of developing colorectal cancer (CRC). Hence, it is 
imperative to find a treatment that not only treats colitis but can also act as a 
chemopreventive agent. Current medications that include aminosalicylates, TNFα 
inhibitors, and corticosteroids help patients cope with the symptoms and induce temporary 
remission, but are paired with a risk of serious side effects and people become refractory. 
Many patients, therefore, turn to unconventional treatments for relief and plant-based 
products provide a safe, alternative option. 
          Many studies have shown that American Ginseng (AG), an herb native to North 
America is effective in the treatment of diabetes, cancer, cardiovascular diseases, and 
neurodegenerative diseases. Our lab has previously shown that AG treats colitis and 
prevents colon cancer in mice. This indicates the potential for AG to become part of 
mainstream medicine like other drugs that have natural antecedents, e.g., taxol, vincristine, 
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digoxin, etc. Drug discovery from plant products involves phytochemical and biological 
characterization of plants used in alternative medicine. This dissertation aims to address 
these issues by identifying the bioactive component of AG and elucidating the mechanism 
of action in the treatment of UC and prevention of CRC. 
          We used bioassay-guided fractionation to identify the most potent fraction of AG. A 
hexane fraction of AG (HAG) has shown remarkable anti-inflammatory and anti-cancer 
properties both in vitro and in vivo. Sub-fractionation of HAG revealed that Panaxynol 
(PA), a polyacetylene is the most abundant compound in this fraction and also showed anti-
inflammatory potential in vitro as indicated by suppression of iNOS, an inflammation 
marker. PA effectively suppressed DSS induced colitis in mice and showed potential as a 
chemopreventive agent. PA targets macrophages (mФ) for DNA damage and apoptosis 
while it requires >10X dosage to sustain cause similar effects in other cell types. 
          AG has been shown to decrease oxidative stress and Nuclear factor (erythroid-
derived 2)-like 2 (NFE2L2 or Nrf2)-a transcription factor that is a master regulator of 
antioxidant response), we hypothesized that AG, HAG, and PA treat colitis by activating 
the Nrf2 pathway. AG, HAG, and PA decreased oxidative stress and activated the Nrf2 
pathway in vitro and in vivo. Accordingly, in vivo experiments indicate that AG, HAG, and 
PA were not very effective in the treatment of DSS induced colitis in Nrf2 knockout mice. 
          We further delineated the mechanism of action of AG in the absence of inflammation 
using gene expression profiling of primary peritoneal mФ by microarray. We found that 
AG and its compounds showed distinct immunomodulatory properties, as shown by the 
activation of both pro-inflammatory cytokines and anti-inflammatory molecules. These 
results will bring AG a step closer to being used as a conventional drug for the treatment 
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of colitis and pave the way for its use in the treatment of other inflammatory and 
autoimmune diseases with a similar genesis.
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CHAPTER 1 
INTRODUCTION 
1.1 GENERAL OVERVIEW 
 Inflammation is the immune system’s first line of defense against foreign pathogens 
or, irritants. Inflammation protects the body against infection and injury by choreographing 
an immune response involving immune cells and cytokines, to eliminate the pathogens 
and/or repair the tissue damage (1,2). The important elements of this response include 
vasodilation to facilitate immune cell filtration and release of cytokines and chemokines 
that elicit an appropriate pro or anti-inflammatory response. The infiltration of 
inflammatory cells like macrophages (mФ) and neutrophils can elicit physical symptoms 
of pain, redness, and swelling (1). These inflammatory cells release cytokines like nitric 
oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) and activate signaling cascades 
involving nuclear factor kappa-light-chain-enhancer of activated B cells (NFκb) and tumor 
necrosis factor (TNF) α, which can eliminate the invading pathogens and repair the tissue 
damage (2–4). 
A genetic predisposition and environmental factors contribute to an overactive 
immune system and associated chronic inflammation. The chronic and cyclical 
inflammation associated with autoimmunity can drive tumorigenesis (5).  More 
specifically, chronic inflammation in the affected tissue increases cancer risk in that tissue.  
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Patients with IBD (UC and CD) have an increased risk of CRC (6).  Studying the 
molecular mechanisms has led to biological therapies including TNF-α inhibitors.  
However, overall treatment outcomes in IBD patients have been modest, people become 
refractory, and there are side effects. Therefore, approximately half of all patients turn to 
complementary and alternative medicines.   
Complementary and Alternative Medicines (CAMs) that includes dietary and 
medicinal supplements like curcumin, grapes, garlic, ginseng, etc., are being explored as 
potential treatments with minimal side effects (7–9). A number of natural products have 
been assimilated into the mainstream medicine for the treatment of various diseases. 
However, CAMs such as plants, herbs, and spices are an amalgam of multiple compounds, 
and it is important to isolate a single, potent component that might be useful as a 
standardized stand-alone treatment, or in a standardized natural cocktail for the suppression 
of colitis.  Mechanisms are also addressable, where this is more difficult with complicated 
mixtures making up natural mixtures. The general low toxicity of plant constituents make 
them candidates for long-term use and therefore the prevention of CRC. Over the past 
several years, our lab has shown that AG can treat UC and prevent CRC in mice. This 
project aims at identifying the bioactive component in AG and delineating the mechanism 
of action of AG and its derivatives.  
1.2 ULCERATIVE COLITIS 
IBDs are chronic, inflammatory, idiopathic diseases that can affect the entire 
gastrointestinal (GI) tract (CD) or just the colon (UC) (10). IBD incidence has been 
increasing since the mid-20th century, indicating the effects of the changing lifestyle and 
dietary habits, including smoking, diets high in fats and sugar, medication, and stress (10). 
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UC has a higher incidence than CD with a rate of 10.2 to 20.3 cases per 100,000 per year 
and a prevalence of 7.6 to 246 cases per 100,000 per year. In the USA, this translates to 1.4 
million people affected (10). The etiology of this disease is unclear but is believed to be 
multifactorial, with genetics, immunological, and environmental (alterations in the 
epithelial barrier, infection, microflora composition, nutrition, stress, etc.) factors playing 
an important role (11). The genetic predispositions can affect the interaction of the immune 
system with microbial and other environmental factors, leading to a disruption in the gut 
homeostasis and this causes an abnormally high proinflammatory response towards the 
commensal bacteria (12). 
Colitis manifests mainly in patients between ages 15-30, but might have a 
secondary peak between the ages of 50-70 and is characterized by inflammation of the 
mucosal layer of the large intestine(13). The clinical symptoms include diarrhea, often with 
blood or pus, abdominal pain and cramping, rectal bleeding and pain, the urgency to 
defecate and inability to defecate despite the urgency, weight loss, dehydration, 
tachycardia, anemia, fatigue, and fever (14). Additionally, there are some extraintestinal 
manifestations of IBD in children and adolescents, which can lead to delayed growth and 
changes in cognitive and sexual development (14). Colitis also has a detrimental effect on 
the quality of life for the patients due to its chronic, recurring nature. However, the most 
important and extreme consequence of colitis is the increased risk of CRC.  The chronic 
inflammatory state of the disease makes an ideal environment for tumorigenesis, and the 
risk of developing CRC increases with the length of disease, with long-term patients facing 
20% risk (12). CRC is the second leading cause of cancer deaths with the prediction of up 
to 50,000 deaths per year (12). Scheduled colonoscopies in colitis patients act as good 
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preventative strategy, but it needs to be paired with potent treatments, which can act as 
chemopreventive agents.  
1.2.1 IMMUNE CELLS IN THE INTESTINE 
The organs with high interaction with the extraneous environment like lungs and 
intestines have additional layers of defenses from the immune system (15,16). The mucosal 
barrier in the intestines, along with the epithelial layer forms the first line of defense against 
the microorganisms and contains the immune cells (neutrophils, monocytes, mФs, 
dendritic cells, natural killer cells, eosinophils, and basophils) responsible for the innate 
immunity (17)(18). These immune cells sample the antigens and elicit an appropriate 
response, which is often short-lived (18). Dendritic cells and mФs in the intestines, along 
with the epithelial cells and myofibroblasts, sense conserved molecular patterns on 
microbes known as pathogen-associated molecular patterns (PAMPs), via pattern 
recognition receptors (PRRs) encoded in the germline (18). This engagement results in the 
initiation of an inflammatory response involving the release of inflammatory cytokines, 
chemokines, and antimicrobial peptides(19). This further leads to the phagocytosis of 
infected cells and pathogens, followed by antigen presentation by dendritic cells to the T-
cells, thereby activating the adaptive immunity (20). The adaptive immune system 
comprises of B-cells and T-cells, which produce antibodies and cytokines, respectively 
(21). 
In the intestine, which faces a constant exposure to a wide array of antigens in food, 
it is important to maintain tolerance to the symbiotic bacteria while also protecting from 
enteric pathogens by eliciting an immune response when needed. Any disturbance in this 
homeostasis can lead to pathogenic diseases like CD and UC (22).  
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1.2.2 MACROPHAGES  
 MФs and dendritic cells belong to myeloid lineage along with neutrophils,  
differentiate from monocytes (23). Monocytes are produced in the bone marrow and are 
abundant in lymph nodes and spleen (24). In the case of an invading pathogen, monocytes 
migrate to the site of infection or damage through the bloodstream and mature into mФs 
through a series of complex differentiation events that require the presence of interleukins 
(IL-1, IL-32, and IL-6) (25–27). Upon their discovery, the main function of mФs was 
thought to be phagocytosis which is essential for wound healing and clearance of 
microorganisms (28). Later, the other main function of mФs, pro-inflammatory cytokine 
production, was identified and is responsible for the initiation of adaptive immunogenic 
response and when left unchecked, leads to prolonged inflammation (29). 
MФ are a diverse group of cells and can be categorized based on their location and 
function into different types, M1 and M2 being the two main categories (30). M1 mФ are 
pro-inflammatory and are considered classically activated or polarized mФ. M1 mФ 
mainly secrete cytokines and protect the host from invading microorganisms and have anti-
tumorigenic properties (31). M1 mФ can be activated by interferon-γ (IFN-γ) (secreted by 
helper T-cells (Th1), cytotoxic T cells (Tc), NK cells and mФ themselves) or 
lipopolysaccharides (LPS) (secreted by bacteria) (32). M1 mФ also enhance the Th1 
response and this response, in turn, enhances the activity of mФs (33). M1 mФ are 
characterized by increased glycolic rate and reduced mitochondrial oxidative 
phosphorylation when compared to the M2 mФs (34). M1 mФs secrete cytokines such as 
IL-1β, tumor necrosis factor (TNF) α, IL-12, IL-18, and IL-23 (31). MФs can also increase 
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the production of nitric oxide from L-arginine, by activating nitric oxide synthase (iNOS), 
resulting in a cytotoxic activity towards various intracellular and extracellular intruders 
such as bacteria, fungi, helminths, viruses, and tumor cells (35). In case of inflammatory 
diseases, M1 mФs are shown to be responsible for the initiation and sustenance of 
inflammation (36).   
M2 mФ (alternatively activated mФ) and are considered anti-inflammatory with 
regenerative properties. M2 mФ are activated as a part of the Th2 response, by IL-4, IL-
13, IL-10, and transforming growth factor (TGF)-β (36). They are involved in tissue 
homeostasis and repair, and have a higher metabolism and are characterized by the 
secretion of high amounts of IL-10 and low levels of IL-12 (37). M2 mФ also produce 
matrix metalloproteases and growth factors to aid in the wound healing (38). 
The mФ in the lamina propria (LP mФs), also known as the resident mФ, are largely 
anti-inflammatory. They have microbicidal activity and clear microbes and other stimuli 
that cross the epithelial barrier (39). However, they do not produce any pro-inflammatory 
cytokines (40). On the contrary, they support the transition from inflammatory to the anti-
inflammatory environment (40). Inappropriate responses from mФ to the gut microbiota 
has been shown to play an important role in the pathogenesis of colitis (41). Enhanced pro-
inflammatory response from the mФs releases nitric oxide (NO), and increases the 
oxidative stress that not only results in the disruption of the epithelial barrier, but also 
subcellular and molecular damage to macromolecules like DNA, RNA, protein, lipids, 
metabolites, etc., thereby contributing to the initiation and maintenance of the disease (42). 
Continued intracellular damage is one of the main causes of transition into colorectal 
cancer. 
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1.2.3 OXIDATIVE STRESS IN ULCERATIVE COLITIS 
An imbalance between the production of free radicals and reactive metabolites, and 
their elimination results in oxidative stress, one of the hallmarks of inflammation (43). This 
imbalance could lead to the damage of important biomolecules and various signaling 
pathways, resulting in a negative impact on the organism (42). Inflammation can induce 
and exacerbate oxidative stress in multiple ways. During chronic inflammation, 
inflammatory cells that are recruited to the site of damage. This recruitment leads to a 
respiratory burst as a result of increased uptake of oxygen, thereby causing an increased 
accumulation of ROS at the site (44). Inflammatory cells also secrete cytokines like 
interleukins, tumor necrosis factor (TNF) α, and interferon (IFN) γ and chemokines like 
CX3-type chemokine receptor (CX3CR) 1, which can, in turn, stimulate the production of 
ROS and RNS (45). For example, TNF-α enhances the formation of ROS by neutrophils 
and other cells, while interleukin-1-β (IL-1-β), TNF-α and IFN-γ stimulate the expression 
of inducible nitric oxide synthase (iNOS) in inflammatory and epithelial cells.  
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) comprise the 
main reactive intermediates, and the antioxidants encompass the protective mechanisms 
responsible for their elimination of these metabolites. ROS are generated by the 
mitochondrial respiratory chain as a part of cellular metabolism and play an important role 
in the alteration of signaling pathways in cells in response to changes in intracellular and 
extracellular environmental conditions (46). When cells are subjected to prolonged 
environmental stress, and ROS are produced over a long period, it results in significant 
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damage to cell structure and also induces somatic mutations that can result in the neoplastic 
transformation of the cells (47). RNS are generated from NO, which is synthesized by 
iNOS, usually after a challenge by immunological or inflammatory stimuli (48). RNS 
increase the risk of mutagenesis by further generating other reactive species, e.g., reactive 
aldehydes-malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), by inducing 
excessive lipid peroxidation (49). Oxidative stress plays thus an important role in the 
initiation and progression of tumorigenesis by increasing DNA mutations or inducing DNA 
damage, genome instability, and cell proliferation. H2O2 is a less reactive but important 
type of ROS that is formed from superoxide anion (O2
-) or spontaneously in peroxisomes 
from molecular oxygen. H2O2 can react with reduced transition metals like Fe+ to produce 
hydroxyl radical (·OH), which in turn can cause DNA damage (50).  
It is important to note that low or moderate levels of free radicals act as a defense 
mechanism against infectious agents by triggering the protective, antioxidant systems and 
signaling pathways. There are multiple endogenous antioxidant systems in place that are 
triggered and regulated by different metabolites. Glutathione reductase (GR), superoxide 
dismutases (SODs), and catalase are the important enzymatic antioxidants that can combat 
and scavenge the free radicals that can cause oxidative stress (51,52). On the other spectrum 
of antioxidant defense are the various transcription factors like AP1, CREB, HSF1, HIF-1, 
TP53, NF-κB, Notch, SP1, and CREB-1 (53). Of these, the Nrf2 (nuclear factor erythroid 
2 [NF-E2]-related factor2)-Keap1 (Kelch-like ECH-associated protein-1) signaling 
pathway, involving the transcription factor, Nrf2, is one of the important regulators of cell’s 
protective responses to oxidative stress (54).  
1.2.4 NRF2 
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The transcription factor, Nrf2 attenuates inflammation by combating oxidative and 
xenobiotic stresses via the activation of multiple antioxidant genes like heme oxygenase 1 
(HO-1) and NAD(P)H Quinone Dehydrogenase 1 (NQO1) (55). HO1 catalyzes the 
degradation of heme and NQO1 catalyzes the reduction of quinones to hydroquinones 
thereby causing detoxification of quinones (56). Nrf2 also controls the expression of 
enzymes involved in the production of glutathione (GSH), the most important antioxidant 
cofactor in cells (56,57).  
 Nrf2 has an extremely short half-life (~15 minutes) resulting in a rapid turnover 
and a slightly longer half-life of ~30 minutes when induced (58). The activity of Nrf2 is 
mainly regulated by Keap-1. Keap-1 is a substrate for a ubiquitin-ligase complex, and by 
sequestering Nrf2, it mediates the proteasomal degradation of Nrf2 (58). Conformational 
changes in the Keap-1 protein can free Nrf2, which can translocate into the nucleus and 
perform its function as a transcriptional factor (58). These conformational changes can 
occur in multiple ways, e.g., ROS can induce the oxidation of cysteine residues or some 
proteins like p62 and p21 can disrupt the binding of Nrf2 to Keap-1, thereby causing the 
activation of the Nrf2 pathway (58). Upon translocation, Nrf2 can bind to the cis-acting 
enhancer antioxidant response element (ARE; core sequence: TGAG/CNNNGC) on 
promoters of the target genes (59). The promoter region of Nrf2 also has two ARE regions 
which it can bind to and auto-regulate the activation (60). 
The importance of Nrf2 in the alleviation of inflammatory diseases is demonstrated 
in various murine models. Deficiency of Nrf2 in mice resulted in exacerbation of 
inflammation in emphysema, pleurisy, and sepsis (61–64). Furthermore, activation of Nrf2 
in myeloid cells resulted in an anti-inflammatory response. Recently, a Nrf2 inducer, 
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Tecfidera, has been approved for the treatment of multiple sclerosis, an autoimmune 
disorder (65). This suggests that Nrf2 activation can be used as a treatment strategy for 
various inflammatory diseases like colitis. 
1.2.5 CURRENT TREATMENTS 
Prolonged inflammation of colitis, when left untreated, can lead to hemorrhage, 
toxic dilation, perforation, and death (12). Various treatments are available for the 
treatment of colitis, depending on the severity of the disease and stage. NSAIDs like 
aspirin, sulindac, and ibuprofen are used to treat the symptoms of pain and inflammation 
for mild flares (12). NSAIDs act by interfering with cyclooxygenase (COX) pathways and 
are not selective towards either of the two isoforms, COX1 and COX2 (12). COX1 is a 
housekeeping gene that plays an important role in cytoprotection by producing 
prostaglandins in various tissues like stomach, duodenum, and kidneys (66). While COX1 
is constitutively expressed in these tissues, COX2 is almost undetectable in normal 
conditions and is induced during inflammation to reach 200-300 times the basal levels (66). 
NSAIDs have adverse effects like mucosal damage and nephrotoxicity with prolonged use 
due to their lack of selectivity (67). 
Moderate flares require steroids which suppress the hyperactive immune system or 
anti-inflammatory drugs like 5-aminosalicylic acid (5-ASA) (68). Severe attacks, 
especially in pediatric patients, require inpatient treatment with intravenous corticosteroids 
and two-thirds of colitis cases may require a colectomy (68). While steroids are effective 
in a short-term use, long-term intake is associated with multiple side effects, like a low rate 
of mucosal healing. 5-ASA is an anti-oxidant that is often ineffective and requires long-
term use to achieve remission (14)(68). 
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More recently, biologics like adalimumab (Humira), certolizumab (Cimzia), 
infliximab (Remicade) and natalizumab (Tysabri) are being used to inhibit inflammation 
(68). The first three biologics mentioned target TNFα, and the fourth targets α4-integrin, a 
cell adhesion molecule (69). However, these biologics, especially the TNFα inhibitors have 
dangerous side effects like increased risk of infections (e.g., tuberculosis) due to suppressed 
immune function (69). Due to the ineffective nature of current treatments, paired with 
dangerous side effects, it is imperative to find a novel, safe, and effective treatment. 
Approximately 50% of patients turn to alternative treatments like acupressure, 
homeopathy, and Tai Chi for solace (70,71). There has also been an increased use of natural 
products like flax seeds, aloe vera, and garlic. Here, we have tested another natural product, 
American ginseng, for its use as an alternative therapy for colitis. 
1.3 AMERICAN GINSENG 
 Ginseng root has been used for centuries in traditional medicine for various 
ailments and general well-being. The botanical name of ginseng, Panax, means ‘all-
healing’ and is closely related to the Greek word ‘panacea.' Ginseng is a mixture of many 
components that include saponins, polyacetylenes, ginseng oils and phytosterol, 
carbohydrates and sugars, organic acids, nitrogenous substances, amino acids and peptides, 
vitamins and minerals, and certain enzymes (72). Among these, saponins (also known as 
ginsenosides) and polyacetylenes have shown to be the active ingredients and have been 
extensively studied for the treatment of multiple diseases including cancer, diabetes, and 
various inflammatory and cardiovascular diseases. Ginseng use is also intended for overall 
health with beneficial effects on immune, cardiovascular, nervous and endocrine systems. 
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 Various species of ginseng are cultivated all over the world; Asian, Korean, or 
Chinese Ginseng (Panax ginseng), notoginseng (Panax notoginseng), and American 
ginseng (Panax quinquefolius) are the most commonly studied species of ginseng. These 
different species of Ginseng vary in their chemical composition, e.g., ginsenosides Rf and 
R1 are present in Korean ginseng and notoginseng but not American ginseng, which 
exclusively contains pseudoginsenoside F11 (73). Furthermore, the ratio of Rg1/Rb1 can be 
used for differentiation between the different species; ratios less than 0.4 indicate American 
ginseng while higher ratios indicate Korean or notoginseng (74). Korean ginseng has been 
used extensively in traditional medicine in Asia for thousands of years while American 
ginseng has been gaining popularity in the Western world in the recent decades for its wide 
range of pharmacological properties. Whole American ginseng root extract and its 
chemical components have been examined as potential treatments. More recently, different 
parts of this plant like fruit, leaves, and flowers are being studied not only for physical 
ailments but also, mental health, general well-being, and cosmetological benefits. 
Like most medicinal plants, American ginseng (AG) has antioxidant properties due 
to which it is effective in the treatment of various diseases where free radicals, like reactive 
oxygen and nitrogen species, contribute to the pathogenesis of the disease. AG can protect 
cardiomyocytes from injury and prevent heart disease by scavenging hydrogen peroxide 
and hydroxyl radicals. AG also decreases oxidative stress in the central nervous system 
(CNS), thereby contributing to the prevention of memory loss. AG has been shown to have 
a hepatoprotective effect by increasing the activity of major antioxidant enzymes, GSH-Px
 
(glutathione peroxidase) and SOD (superoxide dismutase). AG has also been shown to 
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prevent myocardial injury and neurodegeneration by inhibiting various ion channels (Ca+, 
K+, Na+, etc.) in a stereospecific manner.  
1.3.1 AMERICAN GINSENG FOR THE TREATMENT OF COLITIS AND COLON CANCER 
In the past few years, our lab and Dr. Chong-Zhi Wang’s lab at the University of 
Chicago have done separate and parallel studies to explore the potential of AG as a 
treatment for colon cancer (75–84). However, we have focused on investigating AG as a 
treatment for UC and specifically, colitis-induced colon cancer while the research in Dr. 
Wang’s lab concentrated AG’s effect on the different types of colon cancer. Our studies, 
however, have undeniably complemented one another.  Here, I will summarize findings 
from both groups to highlight the significance of AG as a prospective treatment for colitis 
and colon cancer. 
AG has significant anti-inflammatory effects in vitro and in vivo. Incubation of 
ANA-1 mФ with AG, followed by activation with IFN-g (polarizes ANA1 cells into 
proinflammatory M1 type) results in decreased activation of iNOS, eNOS, NO release and 
I-kB, oxidative burst and oxidative stress. Preincubation of HT-29 colon cells with AG 
prevents DNA damage from cytokine-induced inflammatory stress when exposed to M1 
type ANA1 cells. AG mimicked these effects in vivo – aside from suppressing the 
proinflammatory markers mentioned above, AG treatment of DSS treated mice also 
decreased the number of CD+ cells such as T helper cells, monocytes, mФs, and dendritic 
cells in the inflamed colon. One of the mechanisms of action of AG is p53 dependent – AG 
does not cause apoptosis in p53-/- inflammatory cells (NH32) and is not effective in the 
prevention of colitis in p53-/- mice (79,84).  
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We have shown AG decreases the number of macroscopic lesions and the severity 
of microscopic adenomas in an AOM-DSS induced colon cancer model. Upon further 
investigation using protein arrays, it was shown that AG decreases the expression or 
activation of tumor-promoting genes like c-Jun, Pax 2 and ErbB2, while it increases the 
expression of tumor suppressors like PP6C, EphA1, and IRAK1 (80). Others have shown 
that AG attenuates colon cancer in different mouse models – AOM and western (high fat) 
diet-induced colon cancer in A/J mice, high-fat diet induced colon cancer in ApcMin-/+ mice 
(85,86). Treatment of mice with AG in these models increased the phosphorylation of 
EGFR, ERK and AKT and also Bax, which is consistent with increased apoptosis (85). 
More recently, it has been shown that AG also altered the metabolomics and microbiota 
profiles in the AOM/DSS-induced colitis and colon carcinogenesis models. These profiles 
in the AG treatment groups are closer to the water control groups indicating that AG can 
alter the effects that inflammation can have on the microbiota (87). 
1.3.2 FRACTIONATION OF AMERICAN GINSENG 
Our lab used bioassay-guided fractionation to obtain multiple fractions American 
Ginseng and tested their anti-inflammatory properties to identify the most potent ingredient 
in AG. AG was sequentially partitioned against various solvents (hexane, dichloromethane, 
ethyl acetate, water, and methanol) each containing a different composition of active and 
inactive chemical entities. The Hexane fraction of AG (HAG) appeared to be the most 
potent one as evidenced by its ability to suppress iNOS and COX-2 expression in 
proinflammatory (M1) ANA-1 mФ and its cytotoxic effects on RAW264.7 cells (88,89). 
Furthermore, HAG also caused apoptosis of inflammatory cells in a manner comparable to 
the whole AG extract in vitro and in vivo (88). HAG also suppressed DSS-induced colitis, 
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and AOM-DSS induced colon cancer in mice further confirming that HAG contains the 
active ingredient/s responsible for similar effects by AG (88,90). However, the effects of 
HAG can only be partially attributed to p53. HAG caused apoptosis in p53-/- cells, even 
though the effect was significantly lower when compared to cells with wild-type p53. 
Similarly, HAG suppressed DSS-induced colitis in both p53 wild-type and p53 knockout 
mice, with better effects in the wild-type mice.  
Global microRNA (miRNA) comparison of HAG treated HCT-116 colon cancer 
cells with untreated cells showed increased expression of Mir-29b by HAG. Mir29b 
suppresses matrix metalloproteinase-2 (MMP-2), thereby suppressing migration of colon 
cancer cells, indicating a potential for HAG and AG in the suppression of metastasis (81). 
Upon establishing the effectiveness of HAG as a potential fraction containing the bioactive 
ingredient of AG, we further fractionated HAG, and identified Panaxynol (PA) (also 
known as falcarinol and carotatoxin), to be the most abundant ingredient. 
1.3.3 PANAXYNOL 
PA is a polyacetylene found in common food and medicinal plants belonging to 
Apiaceae (e.g., carrots, celery, parsnip, etc.) and Araliaceae (e.g., AG, ivy, etc.) 
families(91). Polyacetylenes are a distinct group of molecules found in medicinal plants 
and have been recognized to have numerous pharmacological properties. PA was initially 
considered a dietary toxin (hence the name, carotatoxin) due to its pro-allergenic effects 
that are responsible for contact dermatitis from common ivy (92). However, the 
concentration of PA in vegetables and roots is lower, and when combined with 
desensitizing effect of oral intake, the risk of an allergic reaction is low (91). More recently, 
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PA is being studied as a potential medicinal drug due to its anti-cancer, anti-inflammatory, 
antimicrobial and neuroprotective properties. 
The anti-cancer effects of PA are evidenced by its antiproliferative and cytotoxic 
effects towards various cancer cell lines such as; leukemia (L-1210), human gastric 
adenocarcinoma (MK-1), mouse melanoma (B-16), renal carcinoma cells (A498, Caki-1, 
and CURC I), and mouse fibroblast-derived tumor cells (L-929) (93–97). However, it is 
not clear how it compares with cytotoxicity towards normal cells as there is conflicting 
data in this regard and appears to depend on the cell lines tested rather than the cell type 
(91,95,98). It is interesting to note that the effect of PA is biphasic in intestinal cells (Caco-
2), where it increased the cell proliferation at doses lower than 10 μM but apoptosis at 
doses higher than 20 μM (99). This biphasic effect conforms to the consensus that toxicity 
is dose-dependent and toxic compounds can have beneficial effects at lower 
concentrations. However, the anti-cancer effect of PA in vivo has not been extensively 
studied. PA from carrots decreased the number of azoxymethane (AOM)-induced pre-
neoplastic lesions in rats and dehydrofalcarinol, a secondary metabolite of PA have been 
shown to have a modest effect on tumors induced in a LOX melanoma mouse xenograft 
model (100,101).   
The mechanism of action of PA has not been elucidated but studies indicate the 
DNA alkylating potential of PA (99), and one of the signaling pathways that could be 
affected is MAP kinase pathway, where PA has been shown to inhibit the phosphorylation 
of ERK1/2 and CREB (102). 
1.4 DSS MOUSE MODEL OF COLITIS  
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 DSS induced colitis is one of the most widely used models to study UC in mice. 
The effect of DSS is limited to the mouse colon and is very similar to that of human colitis 
in etiology, pathology, and clinical outcome (103). The DSS treatment can be manipulated 
to achieve the different types of inflammation (103). For example, treatment with DSS for 
1-2 weeks mimics acute inflammation while treatment with DSS in alternative weeks for 
multiple cycles represents chronic inflammation. We treated mice with DSS before or after 
treating the mice with PA to check the effectiveness of PA as a treatment and preventative 
for colitis respectively. 
 The precise mechanism of action of DSS is unknown but the sequence of events, 
where crypt loss precedes inflammation, suggest that DSS affects the epithelial layer and 
increases permeability (103). There are multiple theories proposed to explain the mode of 
insult to the epithelium by DSS. DSS affects the permeability by disrupting the tight 
junction protein (Zona occulens-1) (104) between the cells or the negatively charged 
sulfate groups in DSS can damage negatively-charged (anionic phospholipids) cell 
membranes by repulsive forces (105). This increased permeability increases the bacterial 
infiltration thereby causing an inflammatory response (105).  It is also believed that the 
anticoagulant nature of DSS increases the intestinal bleeding further exacerbating the 
disease (105). However, the molecular weight of DSS plays an important role in 
determining the severity and extent of colitis, with 35000-50000 being the most effective 
range for inducing colitis (106). 
1.5 OBJECTIVES OF THE RESEARCH 
As discussed earlier, current medications are ineffective in the treatment of colitis and are 
accompanied by a horde of dangerous side effects. In order to find a natural and effective 
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treatment, we have previously tested AG and shown that it successfully suppresses colitis 
in mice. A natural next step is to identify the bioactive component of AG so that it can be 
used as a conventional treatment for colitis. The objective of this research is two-fold –  
1. To identify the bioactive component of AG (Figure 1.1) and  
2. To elucidate the mechanism of action of AG and its components in the treatment of 
colitis (Figure 1.2). 
To this end, the following conclusions have been reached: 
Conclusion 1: PA, a bioactive component isolated from AG, is effective in the treatment 
of DSS induced colitis in mice (Chapter 2) 
Conclusion 2: PA specifically targets mФ for DNA damage and apoptosis. (Chapter 2) 
Conclusion 3: Activation of the Nrf2 pathway is essential for the treatment of colitis by 
AG, HAG, and PA. (Chapter 3) 
To further elucidate the pathways influenced by the action of AG and its 
components, we performed gene expression profiling of primary mФ treated by AG and 
identified the potential targets.
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Figure 1.1. Schematic for the identification of a bioactive component of American 
Ginseng. Bioassay-guided fractionation determined that Hexane fraction of AG was found 
to be the most potent fraction of AG, of which Panaxynol was the most abundant molecule.
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Figure 1.2 Schematic for mechanisms of action of AG and its components. Confirmed 
and potential mechanisms of action of AG, HAG, and PA in the treatment of UC, other 
inflammatory diseases, and cancer. The solid blue line represents previously confirmed 
mechanisms, solid green lines represent mechanisms confirmed in this dissertation, and 
dotted orange lines indicate potential mechanisms. 
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CHAPTER 2 
PANAXYNOL, A BIOACTIVE COMPONENT OF AMERICAN 
GINSENG, TARGETS MACROPHAGES AND SUPPRESSES 
COLITIS IN MICE 
ABSTRACT 
Ulcerative colitis (UC) has a significant impact on the quality of life for the patients, 
and can substantially increase the risk of colon cancer in patients suffering long-term. 
Conventional treatments provide only modest relief paired with a high risk of side effects, 
while complementary and alternative medicines can offer safe and effective options. Over 
the past decade, we have shown that American ginseng, particularly the hexane fraction of 
American ginseng (AG), has anti-oxidant and anti-inflammatory properties that can 
suppress mouse colitis and prevent colon cancer associated with colitis. With the goal of 
isolating a single active compound, we further fractionated the hexane fraction, and found 
the most abundant molecule in this fraction was the polyacetylene, Panaxynol (PA). After 
isolating and characterizing PA, we tested the efficacy of PA in the treatment and 
prevention of colitis in mice and studied the mechanism of action. We demonstrate here 
that PA effectively treats colitis in a Dextran Sulfate Sodium mouse model by targeting 
macrophages (mФ) for DNA damage and apoptosis. Positive outcomes from this study will 
take American ginseng one-step further towards becoming a conventional drug for the 
treatment of colitis, possibly other autoimmune diseases associated with macrophage 
dysfunction, and for the prevention of inflammation-driven carcinogenesis.
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2.1 INTRODUCTION 
Inflammatory bowel diseases (IBDs), including UC and Crohn’s disease (CD), are 
debilitating, significantly affect lifestyle, and carry a high colon cancer risk. IBD 
prevalence is particularly high in North America and Europe (affecting 3.8 million people), 
with an economic burden of $30 - $45 billion (1–4). Of note, incidence has been increasing 
for both males and females over the past 20 years (5), making this a health problem that 
needs to be addressed for both sexes.  As a frustration to patients with IBD, conventional 
treatment outcomes are modest, e.g., 20% do not respond to anti-TNFα antagonists (6), and 
toxicity leads to dangerous side effects. As such, about half of all IBD patients (millions) 
turn to complementary and alternative medicines (CAMs). Although CAMs have been 
used for thousands of years, there is a gap in our knowledge of the mechanisms that support 
their effectiveness. Understanding these mechanisms will not only lead to standardized and 
more efficient treatment for IBD outside of toxic FDA-approved drugs but will also better 
our understanding of the potential applications of CAMs for other diseases with similar 
mechanisms.  
The natural herb, American ginseng (Panax quinquefolius; AG), improves mental 
performance and detrimental endpoints associated with diseases, such as cardiovascular 
disease, diabetes, and influenza (7,8). Over the past decade, we have shown that AG has 
anti-oxidant and anti-inflammatory properties and can suppress mouse colitis and prevent 
colon cancer associated with colitis (9–11). Using bioassay-guided fractionation, more 
recently, we have shown that a hexane fraction of AG (HAG) was particularly potent in 
this capacity (12–14).   
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With a goal of isolating a single, bioactive compound from AG and HAG, we further 
fractionated HAG and found that the most abundant molecule in this fraction was the 
polyacetylene, PA. Polyacetylenes are a distinct group of naturally occurring products, 
whose numerous pharmacological properties have been recognized (15). PA ([3(R)-(9Z)-
heptadeca-1, 9-dien-4, 6-diyn-3-ol]; falcarinol) is a bioactive member of this family. It has 
been identified in both traditional herbal medicines (such as AG), and in common dietary 
plants, e.g., carrots, celery, fennel, parsley, and parsnip (16). Interestingly, PA has been 
shown to have anti-cancer properties (16–19) and neuroprotective effects (20–22). 
However, there remains an unanswered question regarding PA’s potential as an anti-
inflammatory molecule and, therefore, its capacity to suppress chronic inflammatory 
diseases, such as UC. Intriguingly, PA (as compared to the hundreds of other potential 
CAMs currently used with success in animals) not only comes from a natural source, but 
is a single molecule, allowing the potential to be standardized on its own, or in a cocktail. 
What makes this molecule innovative is the putative mechanism we explore here by 
addressing the hypothesis that PA targets mФ for apoptosis resulting in the suppression of 
colitis in mice.   
2.2. MATERIALS AND METHODS 
2.2.1 IDENTIFICATION AND ISOLATION OF PANAXYNOL  
Characterization of HAG and extraction of PA were carried out by our collaborator, 
Dr. Anthony Windust at the National Research Council (Ottawa, ON, Canada). The method 
for characterization and analysis of HAG has been described in detail previously [12]. 
Briefly, for characterization of bioactive components of HAG, this fraction was sub-
fractionated through preparative, reverse-phase HPLC, where the HAG was divided into 
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five sub-fractions based on elution time (4 minutes each). The fractions were collected over 
six repeat runs (6 x 50 mg injected) and evaporated to dryness. A comparative analysis by 
analytical scale LC-UV of both the whole and each sub-fraction was performed to confirm 
identities of constituents in each sub-fraction. 
PA was isolated and purified from Panax quinquefolius grown on the Harper Ranch, 
Kamloops, BC, Canada. The method of extraction and purification of PA has been 
previously described (23). Briefly, dried root of 4-year-old AG was dissolved in ethanol, 
and the organic layer was concentrated using vacuum centrifuge to yield dark brown oil. 
This extract was further separated using flash chromatography, and the fractions containing 
PA were dried to yield crude PA. The crude PA was then subjected to multiple passes of 
chromatography, and the purity of the final extract was validated using liquid 
chromatography with UV diode array detection (LC-UV-DAD). Purified PA was dissolved 
in 95% ethanol for use in in vitro and in vivo experiments. 
2.2.2 CELL LINES AND REAGENTS 
All cells were maintained in appropriate media recommended by ATCC 
supplemented with 10% New Born Calf serum (NBCS) (Biofluids, Rockville, MD), 
penicillin (10 U/ml) and streptomycin (10 μg/ml, Biofluids) at 37°C in a humidified 
chamber with 5% CO2 atmosphere. Experiments with PA were carried out by treating the 
cells with indicated concentrations of PA dissolved in appropriate media with 0.1% NBCS. 
For polarization to M1 type mФ, ANA-1 cells were exposed to 10 ng/ml interferon-γ 
(IFNγ) for 8 hours (R&D Systems, Minneapolis, MN) either before or after the treatment 
with PA. For differentiation of U-937 monocytes into mФ, cells were treated with 10 ng/ml 
phorbol 12-myristate 13-acetate (PMA) (Sigma; P1585) for 24 hours. After replacing with 
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fresh media containing no PMA, the cells were allowed to grow for 48 hours before 
treatment with PA. CD4+CD25- cells were isolated from the spleens of C57BL/6 mice as 
previously described [13]. Briefly, the mФ and B cells were depleted before isolation of 
CD4+CD25- T cells using MACS separator along with CD4 and CD25 microbeads 
(Miltenyi Biotec, Auburn, CA). For co-culture experiments, HCT-116 cells were plated in 
6-well dishes and ANA-1 mФ activated with IFN-γ were placed in the inserts (2018-11, 
Grenier bio-one; Kremsmünster, Austria) to mimic an inflammatory environment.  
2.2.3 WESTERN BLOT ANALYSIS AND ANTIBODIES 
Phospho-Histone H2AX (Ser139) (cat # 9718S), phosphor-p53 (Ser15) (cat # 
9284S), and GAPDH (cat # D16H11) (5174S) rabbit monoclonal primary antibodies 
(1:1000 dilution); and horseradish peroxidase conjugated anti-rabbit secondary antibody 
(7074S) (1:2000 dilution) were purchased from Cell Signaling Technology, Danvers, MA. 
Primary antibody incubations were carried out overnight at 40C Secondary antibody 
incubations were carried out at room temperature for 1 hour. The Western blot signal was 
detected by Pierce ECL Western Blotting Substrate (Thermo Scientific, Rockford, IL) and 
developed onto Hyperfilm (GE Healthcare Life Sciences, Pittsburgh, PA) or imaged using 
Bio-Rad ChemiDoc Imager.  
2.2.4 FLOW-CYTOMETRIC TUNEL ANALYSIS 
TUNEL labeling was performed using Fluorescein in situ cell death detection (cat 
# 11684795910, Roche Diagnostics, IN). Briefly, cells were incubated in 0.1% NBCS 
supplemented media containing appropriate concentrations of PA or vehicle. Cells were 
harvested after 12 hours of treatment, and TUNEL assay was performed as described by 
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the vendor. TUNEL positive cells were detected and quantified using Beckman Coulter 
F500 Flow Cytometer and CXP software. 
2.2.5 IN VIVO EXPERIMENTS 
DSS (MW 36000–50000) obtained from International Laboratories USA (San 
Francisco, CA) was used to induce colitis in mice. 8-10 week old C57BL/6 mice were 
obtained from Jackson Laboratories (Bar Harbor, ME) and maintained in a suitable 
environment according to the Institutional Animal Care and Use Committee (IUCUC) 
standards. The care and usage of the mice were monitored by Animal Resource Facility 
(ARF) at the University of South Carolina, Columbia. This study was approved by IACUC 
(Animal Use Protocol # 2178). 
For the prevention model of colitis, mice were given PA, once daily, at different 
doses (0.01 mg/kg, 0.1 mg/kg, 0.5 mg/kg and 1 mg/kg diluted in ddH2O) by oral gavage 
for two weeks. The lowest dose was calculated based on our previous experiments with 
AG and HAG. The PA dose was equated to reflect the percentage composition of PA in 
HAG. Mice were given 2% DSS in drinking water to induce colitis starting on day 7. For 
the colitis treatment experiments, mice were given 2% DSS in their water for two weeks. 
Starting on day 7, mice were given PA at the same doses as the prevention experiments 
(0.01 mg/kg, 0.1 mg/kg, 0.5 mg/kg and 1mg/kg; Table 2.1) by oral gavage. Control mice 
were given ddH2O by oral gavage. The weight of mice was monitored over the duration of 
the experiment. The mice were sacrificed on day 14 and colons were harvested, length was 
measured and processed for further analysis.  
For macrophage depletion, we administered 200 μl clodronate liposomes in PBS 
via intraperitoneal injection (i.p.) and empty liposomes in PBS were used as a vehicle 
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control. The first injection was on the day -1 with the subsequent injections on days 2, 6, 
10 and 13. DSS was administered starting on day 0 through day 13, and PA treatment was 
given days 7-13. Mice were sacrificed on day 14. 
Blood in stool was detected using Hemoccult (Beckman Coulter) fecal 
immunochemical test. Immediately before sacrifice, stool consistency (0-fully formed 
stool; 2-loose stool; 4-diarrhea) and blood in the stool (0-no blood; 2-detected using 
Hemoccult; 4-rectal bleeding) were scored, and these measurements were used along with 
the weight difference in mice from the beginning to the end of the experiment (0=no weight 
loss; 1= 0-5% weight loss; 2= 6-10% weight loss; 3=11-15% weight loss; 4=16-20% 
weight loss), to calculate the CDI.  
2.2.6 INFLAMMATION SCORING 
Paraffin-embedded colons were serially sectioned (5 µm), and one section from each 
mouse was stained with hematoxylin and eosin. The stained slides were blindly examined 
under a microscope by two investigators (A. Chaparala and A. Chumanevich) for 
histopathological changes and scored according to a system previously described and 
extensively used by our lab and many others (12,24,25). Briefly, the histology score for 
inflammation accounts for four parameters – 1) inflammation severity (0 (no 
inflammation), 1 (minimal), 2 (moderate), and 3 (severe)); 2) inflammation extent (0 (no 
inflammation), 1 (mucosa only), 2 (mucosa and submucosa), and 3 (transmural)); 3) crypt 
damage (0 (no crypt damage), 1 (one-third of crypt damaged), 2 (two-thirds damaged), 3 
(crypts lost and surface epithelium intact), and 4 (crypts lost and surface epithelium lost)) 
and; 4) percentage area of involvement (0 (0% involvement), 1 (1-25%), 2 (26-50%), 3 
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(51-75%), and 4 (76-100%)). The scores for the first three parameters are added and the 
sum is multiplied by the fourth parameter, giving a range of scores between 0-40. 
2.2.7 IMMUNOHISTOCHEMISTRY 
Sections of paraffin-embedded colons were incubated with cyclooxygenase-2 (COX-2) 
(cat # 60126; Cayman Chemical Company, Ann Arbor, MI) CD11b (cat # ab133357; 
Abcam, Cambridge, UK) mouse polyclonal antibody, diluted 1:10,000 in Antibody 
Amplifier™ (ProHisto, LLC, Columbia, SC) overnight. The slides were then processed 
using EnVision+ System HRP kits (DAKO, Carpinteria, CA) according to the instructions 
provided by the kit, which uses the chromagen, diaminobenzidine to elicit dark brown 
reaction to the HRP-tagged secondary antibody provided in the kit. Methyl green was used 
as a secondary stain. Immunoreactivity score was obtained by multiplying scores from two 
criteria – 1) percentage of tissue stained (0-5: 0 (0% positive staining), 1 ( < 10%), 2 (11-
25%), 3 (26%-50%), 4 (51%-80%), or 5 ( > 80%)), and 2) staining intensity (0-3: 0 
(Negative staining), 1 (Weak), 2 (Moderate), or 3 (Strong)). The scores of two parameters 
are multiplied, giving a range of scores between 0-15. 
2.2.8 STATISTICAL ANALYSIS 
Data are expressed as a mean ± standard error of the mean. Mean differences 
between the groups were compared by one-way analysis of variance (ANOVA), followed 
by Dunnett’s multiple comparison tests. A P-value of ≤ 0.05 was chosen for significance. 
2.3 RESULTS 
2.3.1 PANAXYNOL IS THE MOST ABUNDANT AND POTENT ANTI-INFLAMMATORY MOLECULE 
IN AG 
We have previously shown that AG and HAG are effective in the treatment of colitis 
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and prevention of colon cancer (9–14). We have also demonstrated that fatty acids and 
polyacetylenes are both components in AG and HAG (12). In moving forward, to better 
understand the active components of HAG, we have sub-fractionated this fraction of AG 
(Fig 2.1A). Sub-fraction 1 (F1; <10% of the whole HAG) contains multiple minor 
components including two minor polyacetylenes tentatively identified based on UV spectra 
(Fig 2.1B). F2 (30% of HAG) contains two major polyacetylenes, Panaxadiol and 
Panaxydol, and four minor polyacetylenes tentatively identified based on UV spectra (Fig 
2.1C). F3 (24% of HAG) contains a major polyacetylene, PA, and a fatty acid, linolenic 
acid (18:3n3) (Fig 2.1D). F4 (27% of HAG) contains linoleic acid and no detectable 
polyacetylenes (Fig 2.1E). F5 (10%) contains minor fatty acids including saturates, and no 
polyacetylenes (Fig 2.1F). F2 and F3, the only fractions containing major polyacetylenes, 
suppress iNOS induction in ANA-1 mФ polarized to the M1 type with IFNγ (Fig 2.1G), 
which is predictive of colitis suppression (10,12). Of the three major polyacetylenes in F2 
and F3 sub-fractions of HAG, PA was the most abundant (10.2%) (12); therefore, we 
proceeded to test its efficacy as an anti-inflammatory compound. 
2.3.2 PANAXYNOL IS EFFECTIVE AS A TREATMENT FOR COLITIS IN DSS MOUSE MODEL 
Following the isolation of PA from HAG, and an initial screening (iNOS 
suppression in vitro [23]), we tested the efficacy of this compound in the prevention and 
treatment of DSS-induced mouse colitis. In the prevention model, where mice were treated 
with PA for a week before the induction of colitis using DSS (Fig S1A), treatment with PA 
did not inhibit colitis in mice when compared to the control group. Moreover, there was a 
marginal increase in the inflammation score with the highest dose of PA (Fig 2.8 A, B) 
when compared to the vehicle group, indicating that pre-treatment with PA slightly 
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exacerbated DSS-induced colitis. Although we are currently exploring the possible 
mechanism of this finding, it appears caution has to be made when considering PA for any 
chemoprevention purposes. 
Excitingly, PA was very effective in the treatment model of colitis (Fig 2.7 1B), 
where colitis was induced with DSS for a week followed by PA treatment. PA significantly 
decreased the Clinical Disease Index (CDI) (Fig 2.2E) and the inflammation score (Fig 
2.2A, B) in a dose-dependent manner. Colonic inflammation from PA-treated mice was 
limited to the distal end of the colon, while in the vehicle group, inflammation involved a 
larger area. To examine a biomarker of inflammation, we tested each colon section for 
cyclooxygenase-2 (COX-2) immunoreactivity.  There was a decreased expression of COX-
2 with PA treatment (Fig 2.2C, D). When taken together, the results are consistent with the 
hypothesis that PA can be used to treat mouse colitis. To note, we monitored the weights 
of the mice over the course of the experiment and did not observe any unexpected weight 
loss even with the highest dose of PA, indicating the non-toxic nature of PA. 
2.3.3 PANAXYNOL TARGETS MACROPHAGES FOR DNA DAMAGE IN VITRO 
In an effort to identify the mechanism of action of PA, we studied the structure and 
observed that PA is a hydrophobic compound with several sites of potential modification 
that could convert it to a DNA reactive alkylating agent (Fig 2.9). The hydroxide at the 3-
position (C3) can be converted to a α, ß unsaturated aldehyde, which is a Michael acceptor, 
while the double bond between the 9 and 10 position could potentially be converted to an 
epoxide. Furthermore, the hydroxide group on C3 can react with the amino group of nucleic 
acids and alkylate DNA. We, therefore, screened multiple cell types for PA-induced DNA 
damage. Strikingly, PA caused DNA damage, as identified by γ-H2AX expression. 
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However, γ-H2AX induction only occurred in mФ. These included mouse mФ (ANA-1, 
Fig 3A, B; RAW264.7, Fig 3C), primary peritoneal mouse mФ (Fig 3D), and human mФ 
(U-937, Fig 2.3E). For all non-macrophage cells (Fig 3F-K), γ-H2AX induction was not 
seen up to 10 µM PA treatment. As well, when U-937 human monocytes were not 
differentiated to mФ, γ-H2AX induction was also not seen until 10 µM PA treatment (Fig 
3K) when compared to induction at 1 μM in U-937 cells differentiated into mФ (Fig 2.3E). 
This indicated the specificity of DNA damage to mature mФ and not monocytes. PA also 
induced phosphorylation of p53 at Ser15 in ANA-1 cells, further confirming DNA damage 
(Fig 2.10). 
2.3.4 PANAXYNOL SELECTIVELY TARGETS MACROPHAGES FOR APOPTOSIS IN VITRO AND IN 
VIVO. 
Based on the understanding that DNA damage is associated with apoptosis, we 
hypothesized that PA could selectively cause apoptosis in mФ. Results are consistent with 
this hypothesis in two macrophage cell lines (Fig2. 4A – C). Apoptosis was minimal in 
other non-macrophage cells, including HCT-116 cells (Fig 2.4D) and mouse embryonic 
fibroblasts (MEFs) (Fig 2.4E). To examine whether PA selectively causes apoptosis in mФ 
in the presence of other cell types, we carried out a co-culture experiment with ANA-1 mФ 
and colon cancer cells (HCT-116). Figure 4F shows that PA causes apoptosis in ANA-1 
mФ at significantly higher levels than in HCT-116 cells. This property of PA would 
distinguish it from broadly immunosuppressive drugs that are currently on the market for 
the treatment of UC. 
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2.3.5 PANAXYNOL TARGETS MACROPHAGES FOR APOPTOSIS IN VIVO 
To confirm that PA targets mФ in vivo, we used colons from the DSS-induced 
colitis experiment to perform IHC for mФ. We used a CD11b antibody, which is a surface 
marker for mФ and we saw that PA-treated colons have lower expression of CD11b when 
compared to the vehicle group, indicating that PA treatment decreased the number of mФ 
in vivo (Fig 2.2A, B). 
We also conducted a DSS-colitis mouse experiment with clodronate, a compound 
that can deplete mФ. We administered clodronate before treatment with DSS to deplete 
mФ and treated them with PA after inducing colitis with DSS. Macrophage depletion with 
clodronate decreased the intensity of colitis, but we did not see any synergistic effect with 
PA treatment. Interestingly, PA was more effective than clodronate treatment for the 
amelioration of colitis as evidenced by the changes in inflammation score (Fig 2.5 C, D). 
2.4 DISCUSSION 
Currently available treatments for UC have multiple side effects and affect major 
organs like kidneys, liver (hepatitis), and pancreas (pancreatitis) (26). Furthermore, 
immune targeting drugs, e.g., infliximab that targets the TNF pathway, are broadly 
immunosuppressive thereby weakening the immune system, and making the body more 
susceptible to other infections like tuberculosis. We have shown that AG treats colitis in 
mice; however, it is composed of multiple ingredients with diverse effects, making it unfit 
for use as a mainstream drug. Upon examining the different extracts of AG, we identified 
HAG to be the most effective fraction in the treatment of colitis. Further analysis examined 
the various components of HAG. PA, apart from being the most abundant molecule in 
HAG, is also more effective than the whole HAG in suppressing iNOS expression in mФ 
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that are polarized to M1 (pro-inflammatory) type. Hence, testing PA for the treatment of 
colitis is a natural step towards the identification of the bioactive component to treat colitis 
and prevent colon cancer.  
Consistent with our previous studies with AG and UC, we used DSS-induced mouse 
colitis model for studying the effect of PA on an inflammatory disease. We found that PA 
treats DSS-induced colitis in the mouse, as seen by decreased CDI, inflammation, COX-2 
expression, and the halted weight loss in treated mice. There was no toxicity even at higher 
doses, as observed by the insignificant weight changes. In future experiments, we will 
examine the effect of PA on liver and kidneys to rule out possible toxicity. 
One of the mechanisms by which AG and HAG treat colitis is by targeting immune 
cells for apoptosis (11,13). We also examined the structure of PA and identified it to be a 
hydrophobic compound, is a potential DNA-reactive alkylating agent. PA and its 
derivative, falcarindiol, have previously been shown to be protein-alkylating agents (27). 
Furthermore, it has been shown that PA causes DNA damage in CaCo2 cells (28). It can 
be reasoned that the mechanism of action of PA can be via the induction of DNA damage. 
Our preliminary results show that PA causes DNA damage in multiple cell lines and that 
mФ are especially sensitive to DNA damage induced by PA. We predict that one possible 
anti-inflammatory mechanism of action of PA is targeting mФ for DNA damage and 
apoptosis. This is an interesting finding with this property being unique to PA. 
Furthermore, we also show that mФ are more sensitive to apoptosis by PA. We also saw 
in our preliminary experiments that treatment with Panaxynol increases the 
phosphorylation of p53 at Ser15 (Fig. S4). This indicates activation of p53 as a result of 
DNA damage and the activated p53 can then induce apoptosis or cause growth arrest. In 
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this case, p53 is possibly causing activation of apoptosis pathway. This further indicates 
that γ-H2AX was possibly induced because of DNA damage, and not the disintegration of 
DNA resulting from apoptosis. 
PA, however, did not prevent colitis in mice. Furthermore, treatment with the highest 
dose of PA slightly increased the inflammation score when compared to the untreated mice. 
The resident mФ in the lamina propria of the intestine are anti-inflammatory and important 
for the maintenance of homeostasis. They clear any microbes and other stimuli that cross 
the epithelial cell barrier, mainly by phagocytosis, but do not secrete any cytokines (29). 
Since PA targeted mФ before induction of colitis in the prevention model, the disease was 
more severe, and PA was ineffective. This is consistent with previous studies that showed 
that depletion of mФ before induction of colitis resulted in exacerbated DSS-induced colitis 
(30). However, upon initiation of UC, there is increased accumulation of proinflammatory 
mФ that secrete cytokines to enhance the inflammatory response. An overactive response 
by the mФ to the enteric microbiota at this stage greatly contributes to the pathogenesis of 
colitis (31). Treatment with PA to target mФ at this stage was highly effective in 
suppressing colitis.  
The reason for the mФ being specifically targeted by PA is not completely understood. 
Future directions will explore the mechanisms of DNA damage and a possible defect in 
DNA repair. Investigating whether PA can prevent colon cancer is the next natural step, as 
macrophage depletion not only decreases inflammation but also suppresses tumorigenesis 
in AOM-DSS-induced model of colitis induced colon cancer in mice (32). PA is effective 
in the treatment of colitis and does so by targeting mФ for DNA damage and apoptosis. 
We have tested a range of doses (0.01 mg/kg – 1 mg/kg), and demonstrate that PA is very 
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effective at 0.1 mg/kg, which would translate to 6 mg for an average patient weighing 60 
kg. This is an extremely low dose when compared to the immunosuppressive drugs 
currently available, placing PA a step above the other treatments for UC. 
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Figure 2.1. Isolation and characterization of various sub-fractions of HAG. A-F) LC-
UV/DAD analysis of Hexane fraction and each sub-fraction. F1 to F5 represent the 
collected fractions, 4 minutes each. Peak identities: Panaxadiol (1), Panaxydol (2), PA (3), 
linolenic acid (4), linoleic acid (5) Column C-18 2.1 x 100 mm, 1 µl injection of a 5 mg 
mL-1 (whole) or equivalent fraction, gradient 55% to 90% acetonitrile/water in 15 minutes; 
hold 5 minutes; re-equilibration 10 minutes. Note: The scale magnification for sub-
fractions 1 and 5 is 2X. G) Effect of HAG and different sub-fractions of HAG on IFNγ-
induced iNOS expression. ANA-1 mouse mФ were incubated for 12 hours with HAG or 
the indicated sub-fractions (10 µg/ml), washed, then exposed to IFNγ (10 ng/ml) for 0, 2, 
and 4 hours. C+ indicates the positive control, which is ANA-1 cells induced by IFNγ, and 
then incubated with media.
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Figure 2.2. Panaxynol suppresses DSS-induced colitis in mice. A) Representative 
images (magnification – 100X) of histological sections from 3 groups; water, DSS only 
and highest dose of PA (1 mg/kg/day). B) Inflammation scores obtained from H & E slides 
of the colon cross-sections. C) Representative images of sections stained for COX-2 
(magnification – 400X). D) Immunoreactivity score (IRS) of COX-2 from IHC staining. 
E) Clinical Disease Index (CDI) accounts for weight loss, blood in stool and stool 
consistency (n=8). Values represent mean ± SEM. One-way ANOVA followed by 
Dunnett’s test was used for comparison between samples. p-value when compared to DSS 
group is indicated by: * = <0.05, ** = <0.01, *** = <0.001, **** = <0.0001.
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Figure 2.3. Panaxynol induces γ-H2AX in macrophages, but not in other cell types. 
All cell types were treated with PA at specified doses for 12 hours. Activated mФ were 
generated by treating with IFNγ (10 ng/ml for 8 hours) before PA treatment. U-937 cells 
were treated with 10 ng/ml PMA for 24 hours for differentiation into mФ. Nuclear protein 
extract from HCT116 cells overexpressing Flag-tagged γ-H2AX was used as a positive 
control for γ-H2AX. A-E) MФ showed increased DNA damage with doses starting from 1 
µM, as shown by the increase in the expression of γ-H2AX, a sensitive marker of DNA 
damage. F-J) Non-macrophage cell lines, including other immune cells (i.e., lymphoblasts 
and T cells) and epithelial cell lines, did not show any change in the protein expression of 
γ-H2AX and K) U-937 cells which are monocytes were more sensitive than U-937 mФ. 
47 
 
  
 
 
Figure 2.4 Panaxynol induces apoptosis in macrophages, but not in HCT-116 and 
MEF cells. Cells were treated with PA for 12 hours with indicated doses. PA significantly 
increased the percentage of apoptotic cells in A) unstimulated ANA-1 cells at 50 µM (18%) 
and 100 µM (70%), B) IFNγ stimulated ANA-1 cells at 10 µM (3.3%) and C) RAW264.7 
cells at 50 µM (50%) and 100 µM (99%). D) PA had no significant apoptotic effect on 
HCT-116. E) PA induced apoptosis in MEFs only at a high dose of 100 µM (9.5%).F) In 
a co-culture experiment, PA caused apoptosis only in ANA-1 cells, but not HCT-116 cells. 
p-value indicated by; * = <0.05, ** = <0.01, *** = <0.001, **** = <0.0001.
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Figure 2.5 Panaxynol targets macrophages in vivo. Effect of PA on macrophages in vivo. 
A) Representative images of sections stained for CD11b (magnification – 400X) (N=8). B) 
Immunoreactivity score (IRS) of CD11b from IHC staining. C, D) DSS mice were treated 
in the presence and absence of clodronate (which depletes macrophages) to assess the 
involvement of macrophages in the treatment by PA. C) CDI). C) Clinical Disease Index 
(CDI) accounts for weight loss, blood in stool and stool consistency (n=6-8). D) 
Inflammation scores obtained from H & E slides of the colon cross-sections. Values 
represent mean ± SEM. One-way ANOVA followed by Dunnett’s test was used for 
comparison between samples. p-value when compared to DSS group is indicated by: * = 
<0.05, ** = <0.01, *** = <0.001, **** = <0.0001.
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Figure 2.6 Schematic of the mechanism of action of Panaxynol. PA targets macrophages 
for DNA damage and apoptosis, thereby decreasing the inflammation and treating UC in 
mice. 
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SUPPLEMENTAL FIGURES FOR CHAPTER 2 
 
 
 
 
 
 
 
 
C) 
 
 
 
 
 
Figure 2.7: Schematics of in vivo experimental courses. A)  Prevention model of colitis 
where the mice were treated with PA before induction of colitis using 2% DSS. B) 
Treatment model where mice were treated with PA after the manifestation of the disease 
due to DSS treatment. C) Clodronate experiment model where mice were treated with 
clodronate liposomes intermittently as indicated.
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Table 2.1 Treatments and conditions for each group. n = 8 
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A)                      B) 
 
 
 
Figure 2.8: Panaxynol does not prevent colitis in mice. A) Representative images of H 
& E stained sections of colons (100X). B) Inflammation scores obtained from H & E 
slides of the colon cross-sections. 
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Figure 2.9: Structure of Panaxynol  
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Figure 2.10: Treatment with Panaxynol increases the phosphorylation of p53 at 
Ser15 in ANA-1 cells. ANA-1 cells were treated with 10ng/ml IFNγ for 8 hours for 
activation of M1 type mФ (B).  
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CHAPTER 3 
AMERICAN GINSENG AND ITS COMPONENTS TREAT COLITIS 
IN MICE BY INDUCING NRF2 DEPENDENT ANTIOXIDANT 
RESPONSE 
ABSTRACT 
Ulcerative colitis (UC) is a chronic, inflammatory, bowel disease that affects 
millions of people worldwide and increases the risk of development of colon cancer. We 
have previously shown that American Ginseng (AG) can treat colitis and prevent colon 
cancer in mice. We further fractionated AG and identified the most potent fraction, Hexane 
fraction (HAG), and the most potent compound in this fraction, Panaxynol (PA). Oxidative 
stress plays a significant role in the initiation and progression of colitis and contributes to 
tumorigenesis. Nrf2 is the master regulator of antioxidant response and hence plays an 
important role in the resolution of inflammation. To further the understanding of the 
mechanism of action of AG and its components, we examined the role of Nrf2 in the 
treatment of colitis. We determined the activation of the Nrf2 pathway and relieving 
oxidative stress in vitro and in vivo. We also used Nrf2 knockout mice to determine if Nrf2 
is essential for AG and its components to operate. We found that AG and its components 
activate the Nrf2 pathway and decrease the oxidative stress in macrophages (mФ) and 
colon epithelial cells. Consistent with these in vitro results, the Nrf2 pathway is activated 
combined with decreased oxidative stress in the DSS-induced colitis mice treated with AG, 
HAG or PA. Moreover, these compounds were not effective in the treatment of colitis in 
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the absence of Nrf2, when compared to the wild-type mice, further establishing Nrf2 as an 
important mediator of AG, HAG, and PA in the treatment of colitis.  
3.1 INTRODUCTION 
Inflammatory bowel disease (IBD), with rectal bleeding, severe diarrhea, and 
weight loss, debilitates approximately 2.6 million people in North America (1), with a 
health care cost of more than $3.9 billion annually. The worldwide health care cost is more 
than $46 billion annually. Treatment strategies for colitis (and the prevention of colon 
cancer) reduce periods of active disease and maintain remission, but outcomes are 
marginal. Patients become refractory, and there are dangerous side effects like cancer, 
infection, sepsis, hepatitis, and death (2–5). To this end, many colitis patients turn to CAMs 
to suppress the disease. 40- 50% of IBD patients use some form of CAM (6,7). Identifying 
new treatments that have minimal toxicity to treat the disease and prevent colon cancer, 
therefore, remains a high priority.  
Previously, we demonstrated that American Ginseng (AG), may be ideally suited 
to treat IBD due to its ability to suppress colonic inflammation without apparent toxic side 
effects in mice (8–10). In further delineating the active components of AG, a fraction of 
AG (AG Fraction V), derived from extraction with n-Hexane as the solvent, was 
particularly potent in suppressing colitis and preventing colon cancer in mice (11–13). We 
have also seen that PA, an abundant molecule in this fraction suppresses colitis in mice. 
The next logical step is to explore the molecular mechanisms of the beneficial effects of 
AG and its components on the treatment of UC. 
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The etiology of UC remains to be fully elucidated, but involves interactions among 
genetic, environmental and immune factors, leading to uncontrolled, abnormal immune 
responses in the intestinal mucosa (14). Chronic intestinal inflammation is associated with 
enhanced RNOS production, and the consequent oxidative stress plays a critical role in the 
pathophysiology of IBD in both animals and humans. For example, elevated RNOS 
(reactive oxygen and nitrogen species) formation in colonic mucosa occurs at an early stage 
of IBD and correlates with the disease severity (15–17). Prevention of IBD has been shown 
by transgenic overexpression of endogenous antioxidant genes and administration of 
antioxidant compounds (18–21).  
Nuclear factor E2-related factor 2 (NRF2), a master regulator of antioxidant 
response element, is a member of the cap'n collar family of basic region-leucine zipper 
transcription factor(22). As a transcription factor, NRF2 promotes the expression of phase 
II antioxidant enzymes that include, but not limited to, NAD(P)H quinone oxidoreductase-
1 (NQO1), heme oxygenase-1 (HO-1), glutamate cysteine ligase (GCL), glutathione S-
transferase (GST), and glutathione peroxidase (GPx), which all protect against reactive 
nitrogen and oxygen species (RNOS). The precise mechanisms of Nrf2 activation are not 
fully understood, but it is widely accepted that Keap1 is a key regulator of Nrf2 (23–25). 
Nrf2 is normally associated with Keap1 that serves as an adaptor for the interaction of the 
Cul3-based E3-ubiquitin ligase complex with Nrf2 leading to Nrf2 ubiquitination then 
proteasomal degradation (26). With various stresses or ARE inducers, the system is 
perturbed, and Nrf2 escapes from Keap1-mediated ubiquitination, accumulates in the 
nucleus, leading to increased Nrf2 target gene transcription(26). Several and probably 
overlapping mechanisms for Nrf2 nuclear accumulation in response to oxidative stress or 
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inducers like a direct modification of cysteine (Cys) residues of Keap1, Nrf2 
phosphorylation of Nrf2, etc. (27–29).  
With Nrf2 being an important initiator of antioxidant response required for the 
treatment of UC, it is reasonable to hypothesize Nrf2 plays an important role in the 
mechanism of action of AG, HAG, and PA. Here, we have shown that AG and its 
components (HAG and PA) suppress oxidative stress via activating Nrf2, a key endogenous 
regulator of antioxidant defenses, both in vitro and in vivo. We have also demonstrated that 
AG and its components suppress colitis by activation of the Nrf2 pathway. We used Nrf2 
knockout mice to demonstrate that AG and its components are ineffective in treating colitis 
in the absence of Nrf2. 
3.2 MATERIALS AND METHODS 
3.2.1 CELL CULTURE 
All cell lines were maintained in cell culture media supplemented with 10% fetal 
bovine serum (FBS) and 1% penicillin and were kept at 37°C in a humidified incubator 
with 5% CO₂. ANA-1 cells were grown in Dulbecco's modified Eagle's medium (DMEM, 
Hyclone, Logan, UT) and HCT-116 cells were cultured in Roswell Park Memorial Institute 
(RPMI)-1640 media. ANA-1 cells were activated by treatment with 10 ng/ml interferon 
(IFN)-γ (R&D Systems, Minneapolis, MN) for 8 hours. AG/HAG/PA was dissolved in 
media and incubated with cells at specified concentrations for indicated times. For co-
culture experiments, HCT-116 cells were plated in 6-well dishes and twice the number of 
activated ANA-1 cells were placed in the transwell inserts (cat # 2018-11, Grenier bio-one; 
Kremsmünster, Austria) to facilitate the exchange of cytokines and other cellular 
secretions.  
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3.2.2 TOS DETECTION: 
ANA-1 mФ were pre-treated with AG, HAG or PA for 12 hours in 6-well dishes. 
The media was replaced with media containing IFN-γ (10 ng/ml), and the cells were treated 
for 1 hour, 2 hours and 3 hours and processed according to the instructions of the 
Superoxide/TOS Chemiluminescent kit (lot # 101214A; Applied Bioanalytical labs. 
Briefly, the cells were washed with PBS and resuspended in Hanks’s buffered saline 
solution (HBSS). Luminol and enhancer solutions were added before measuring the 
luminescence in a luminometer at 425nm. Luminometer quantifies an oxidative burst 
through the reaction of luminol with reactive oxygen species to produce a luminophore. 
Luminescence intensity is proportional to the number of reactive species 
in the sample and is quantified as relative light units. 
3.2.3 WESTERN BLOT: 
The primary antibodies, HO- 1 (ab13248; Abcam, Cambridge, UK) and GAPDH 
(5174S; Cell Signaling, Danvers, MA) were diluted to 1:1000 and incubated with the 
membrane overnight at 40C. Horseradish peroxidase-conjugated anti-rabbit secondary 
antibody (7074S; Cell Signaling, Danvers, MA) at 1:2000 dilution was incubated at room 
temperature for 1 hour. The Western blot signal was detected by Pierce ECL Western 
Blotting Substrate (Thermo Scientific, Rockford, IL) and imaged using Bio-Rad 
ChemiDoc Imager.  
3.2.4 IMMUNOFLUORESCENCE: 
Cells (5x105/well) were seeded into six well plates containing a coverslip. The next day,  
cells were rinsed with ice-cold  PBS  and fixed with  4%  paraformaldehyde for  10  min at 
room temperature,  followed by permeabilization with  0.1%  Sodium  Citrate with  0.1%  
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Triton  X-100.  The cells were incubated with Nrf2 antibody at 1:1000 dilution (12721S; 
Cell Signaling, Danvers, MA) for one hour at room temperature. The cells were then 
washed with cold  PBS  three times (5 minutes each),  and incubated with  Alexa  514-
labeled  anti-rabbit secondary antibody (1:1000) (Invitrogen) at room temperature for 1 
hour. The cells were then incubated with conjugated actin antibody for 15 minutes. After 
washing with PBS, the coverslips were mounted onto the slides with ProLong™ Diamond 
Antifade Mountant with DAPI (P36962; Thermo Fisher Scientific). The cells were 
examined by fluorescence microscopy  (Olympus  America  Inc, Center  Valley,  PA). 
Fluorescence  intensities  from  images  of six   randomly   selected   microscopic   fields 
of cells   were   semi-quantitatively   analyzed   by densitometry (ImageJ software, NIH) 
3.2.5 IMMUNOHISTOCHEMISTRY: 
For immunohistochemical staining, serial sections of mouse colon tissues 
(processed as described above) were incubated with anti-HO-1 (ab13248; Rabbit 
Polyclonal, diluted 1:2000; Abcam, Cambridge,UK), 4-Hydroxynonenal (4-HNE) 
(ab46545; Rabbit Polyclonal, diluted 1:1000;Abcam, Cambridge, MA), and COX2 (Rabbit 
Polyclonal, diluted 1:1000cat # 60126; Cayman Chemical Company, Ann Arbor,MI). To 
ensure even staining and reproducibility, sections were incubated by slow rocking 
overnight in primary antibodies (4°C) using the Antibody Amplifier™ (ProHisto, LLC, 
Columbia, SC).Sections were processed with EnVision+ System-HRP kit according to kit 
protocols(K4011; Dako Cytomation, Carpinteria, CA). Immunohistochemistry was 
quantified as described previously (11). 
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3.2.6 RNA ISOLATION AND RT Q-PCR 
 The cells were lysed using Trizol and RNA was isolated using the RNeasy mini kit 
(Cat # 74104; Qiagen, Hilden, Germany) according to the instructions. RNA 
concentrations were measured using NanoDrop 2000 spectrophotometer (Thermo Fisher 
Scientific). 1μg of RNA was used for cDNA synthesis using iScript cDNA synthesis kit 
(cat # 1708890; Bio-rad, Hercules, CA). The final product was diluted 1:10 for qPCR. 
qPCR was performed using iTaq™ Universal SYBR® Green Supermix (cat #1725121; 
Bio-rad, Hercules, CA). The list of primers used is as follows in the order forward then 
reverse in 5`-3` orientation.  – HO-1: AAGCCGAGAATGCTGAGTTCA, 
GCCGTGTAGATATGGTACAAGGA; NQO1: AGGATGGGAGGTACTCGAATC, 
AGGCGTCCTTCCTTATATGCTA; Nrf2: TCTTGGAGTAAGTCGAGAAGTGT, 
GTTGAAACTGAGCGAAAAAGGC; GAPDH: AGGTCGGTGTGAACGGATTTG, 
TGTAGACCATGTAGTTGAGGTCA. Human primers – HO-1: 
CCACCTGTTAATGACCTTGCC, CACCGGACAAAGTTCATGGC; NQO1: 
GAGGCCAAATCAGGCTTACGG, CACTCCTGTCCACCAATCGC; GAPDH: 
AATCCCATCACCATCTTCCA, TGGACTCCACGACGTACTCA. qPCR was 
performed on CFX384 Touch™ Real-Time PCR Detection System (cat # 1855485; Bio-
rad, Hercules, CA).  
3.2.7 DSS-INDUCED COLITIS MOUSE MODEL 
C57BL/6 and Nfe2l2tm1Ywk were obtained from The Jackson Laboratory. All 
mice were on an AIN93M diet as described previously. The mice were either given water 
ad libitum or 2% DSS for two weeks, starting on day 0. Treatments with AG (75 
mg/kg/day), HAG (75 mg/kg/day) and PA (1mg/kg/day), dissolved in PBS, were carried 
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out by oral gavage from day 7-13. The control groups were treated with 1x PBS by oral 
gavage as well. All procedures performed were in accordance with the Guide for Care and 
Use of laboratory animals (National Research Council, Washington, DC) and by the 
approval of the Animal Resource Facility, University of South Carolina, Institutional 
Animal Care and Use Committee. On the day of the sacrifice, stool consistency (0-fully 
formed stool; 2-loose stool; 4-diarrhea) and blood in the stool (0-no blood; 2-detected using 
Hemoccult; 4-rectal bleeding) were scored, and these measurements were used along with 
the weight difference in mice from the beginning to the end of the experiment (0=no weight 
loss; 1= 0-5% weight loss; 2= 6-10% weight loss; 3=11-15% weight loss; 4=16-20% 
weight loss), to calculate the CDI. Blood in stool was detected using Hemoccult (Beckman 
Coulter) fecal immunochemical test. Mice were sacrificed on day 14 and colons were fixed 
overnight in formalin after they were cut longitudinally and their lengths were measured. 
The colons were then embedded in paraffin for sectioning. 
3.2.8 INFLAMMATION SCORING 
Paraffin-embedded colons were serially sectioned (5 µm), and one section from each 
mouse was stained with hematoxylin and eosin (H&E). The stained slides were blindly 
examined under a microscope by two investigators (A. Chaparala and A. Chumanevich) 
for histopathological changes and scored according to a system previously described 
(12,24,25). Briefly, the histology score for inflammation accounts for four parameters – 1) 
inflammation severity (0 (no inflammation), 1 (minimal), 2 (moderate), and 3 (severe)); 2) 
inflammation extent (0 (no inflammation), 1 (mucosa only), 2 (mucosa and submucosa), 
and 3 (transmural)); 3) crypt damage (0 (no crypt damage), 1 (one-third of crypt damaged), 
2 (two-thirds damaged), 3 (crypts lost and surface epithelium intact), and 4 (crypts lost and 
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surface epithelium lost)) and; 4) percentage area of involvement (0 (0% involvement), 1 
(1-25%), 2 (26-50%), 3 (51-75%), and 4 (76-100%)). The scores for the first three 
parameters are added, and the sum is multiplied by the fourth parameter, giving a range of 
scores between 0-40. 
3.2.9 STATISTICAL ANALYSIS 
Data are expressed as a mean ± standard error of the mean. Mean differences 
between the groups were compared by one-way analysis of variance (ANOVA), followed 
by Dunnett’s multiple comparison tests. A P-value of ≤ 0.05 was chosen for significance. 
3.3 RESULTS 
3.3.1 AMERICAN GINSENG AND ITS DERIVATIVES ACTIVATE NRF2 PATHWAY IN 
MACROPHAGES 
We have previously shown that American Ginseng decreases total oxygen species 
in mФ activated to M1 type by IFN-γ. Here, we show that ANA-1 cells pre-treated with 
HAG and PA also show decreased total oxygen species when stimulated with IFN-γ 
(Figure 3.1 G). Antioxidant response mediated by Nrf2 is the most important phenomenon 
that is responsible for defense against inflammation. We hypothesize that American 
Ginseng and its components, HAG and PA decrease the reactive oxygen species by 
activating the antioxidant response via Nrf2. To test this hypothesis, we looked at the 
translocation of Nrf2 into the nucleus as well as activation of a key target gene activated 
by this transcription factor. Immunofluorescence data shows that Nrf2 is localized to the 
nucleus upon treatment with AG, HAG or PA, indicating its activation (Figure 3.3A). HO-
1, a target of Nrf2, is upregulated by AG, HAG and PA treatment of ANA-1 mФ, as shown 
by immunoblot and qPCR and immunoblot (Figure 3.3 B, D). Nrf2 has two ARE elements 
in its promoter region, and the elevated expression of Nrf2 gene indicates self-activation, 
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as seen in Figure 3.3C. To check the activation of Nrf2 in epithelial cells in an inflammatory 
environment, we co-cultured HCT-116 cells with activated ANA-1 cells for 3 hours. RT-
qPCR data indicates that Nrf2 and HO-1 show increased expression when HCT-116 cells 
were pre-treated with AG, HAG, or PA (Figures 3.3 E, F). 
3.3.2 AMERICAN GINSENG AND ITS DERIVATIVES SUPPRESS OXIDATIVE STRESS AND 
ACTIVATE NRF2 PATHWAY IN VIVO 
To evaluate if Nrf2 is activated by the AG, HAG, and PA in vivo, we used DSS 
induced colitis mouse model. We used previously tested doses of AG (75 mg/kg/day), 
HAG (75 mg/kg/day) and PA (1 mg/kg/day) to treat mice by oral gavage. The colons were 
probed for 4-hydroxy-2-nonenal (4HNE) and HO-1. 4HNE is a product of lipid 
peroxidation and a biomarker for cellular oxidative stress; and HO-1, as indicated above, 
is a target of Nrf2. We see the decreased expression of 4HNE in the treatment groups 
indicating reduced oxidative stress (Figures 3.2A, B). We also see increased expression of 
the HO-1 protein, indicating the activation of the Nrf2 pathway (Figures 3.2C, D). 
3.3.3 AMERICAN GINSENG AND ITS DERIVATIVES SUPPRESS COLITIS BY ACTIVATING NRF2 
PATHWAY 
We have previously shown that AG, HAG, and PA suppress DSS induced colitis in 
mice. Nrf2 activation is important for the antioxidant response, which in turn is important 
for defense against inflammation caused by ulcerative colitis. Since AG and its derivatives 
activate Nrf2 pathway in vitro and in vivo, we hypothesized that their mechanism of action 
requires activation of Nrf2 mediated anti-oxidant response. To test this hypothesis, we 
compared the effectiveness of AG, HAG, and PA in the treatment of DSS induced colitis 
in wild-type with that of their effectiveness in Nrf2 knockout mice. We used the previously 
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described 14-day DSS induced colitis mouse experiment (Figures 3.3A, B). AG, HAG, and 
PA lowered the CDI in wild-type mice but not in the Nrf2 knockout mice (Figure 3.3 C). 
We scored inflammation as indicated by ulceration, damage to crypts, and infiltration by 
inflammatory cells, using H and E slides of colon sections. Treated wild-type mice had 
significantly lower histology score than DSS-only mice, while the treatment was not as 
effective in case of Nrf2 knockout mice (Figures 3.4 A, B). We also tested 
immunoreactivity of COX2, a proinflammatory enzyme that has elevated protein 
expression during inflammation. We see that AG, HAG, and PA effectively decrease COX-
2 expression in wild-type mice, but not the Nrf2-/- mice (Figures 3.4 C, D). Put together, 
this confirms that AG and its derivatives treat DSS induced colitis in mice by activating 
the Nrf2 pathway.  
3.4 DISCUSSION 
  Deregulation of intestinal immune responses is considered a major contributor to 
IBD; the mechanisms of which are not well understood. A better understanding of this 
phenomenon would lead to better treatment strategies and would help millions of people, 
and reduce the tremendous cost of treatment with small synthetic molecules. Because IBD 
(aka colitis) is, by definition, chronic colon inflammation, it is reasonable that antioxidant-
based approaches have shown efficacy in treating IBD (30). Current FDA-approved 
therapies involve treatment with 5-aminosalicylic acid (5-ASA) and its analogs, as well as 
glucocorticosteroids and anti-TNFα biologicals. Such treatment reduces periods of active 
disease and helps to maintain remission. Although these drugs have modest beneficial 
effects, patients become refractory, and there are significant side effects (31). This 
underscores the importance of developing more effective IBD therapies. To this effect, we 
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have explored the potency of a natural compound, AG in the treatment of colitis and 
identified the bioactive components that could be responsible for AG’s efficacy. The 
identification of a single, active component would bring AG a step closer to being used as 
a mainstream medicine.  In this context, it makes sense and would be significant to explore 
the molecular mechanisms of AG-mediated beneficial effects on the treatment of IBD. 
An increased susceptibility also shows a key role of endogenous antioxidants in controlling 
intestinal inflammatory stress to chemically induced IBD and associated colon cancer in 
Nrf2-/- mice (32,33). As Nrf2 is a central regulator of tissue antioxidant defenses (23), 
these studies not only support a causative role of oxidative stress in IBD but also suggest 
that targeting Nrf2 provides a novel antioxidant-based intervention of IBD and the 
chemoprevention of colon cancer. AG and other plant products like resveratrol have been 
shown to combat cellular stress by activating the antioxidant mechanisms in the cell. 
Korean ginseng has been shown to activate Nrf2 pathway (34,35), and we have previously 
demonstrated with our collaborators that AG can activate Nrf2 in cardiomyocytes (36). 
Since AG and HAG are anti-inflammatory and suppress many of the molecular targets of 
Nrf2 (9–12,37,38), it is reasonable that Nrf2 is at the crossroads of the protective effects of 
AG/HAG/PA, and colitis-associated carcinogenesis. Nrf2 mediated antioxidant response 
plays an important role in resolving inflammatory diseases and could play an important 
role in AG mediated treatment of colitis. 
In this study, we measured the antioxidant response and activation of Nrf2 signaling 
pathway upon treatment with AG and its components, macrophage cell lines (in vitro), and 
mouse colon (in vivo). Treatment with AG, HAG, and PA activated HO-1 in ANA-1 
macrophage cell lines and mouse colons with DSS induced colitis. They also induced the 
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translocation of Nrf2 into the nucleus, indicating its activation. Furthermore, we saw that 
these treatments also decreased the production of TOS in vitro, and the expression of 4HNE 
in vivo indicated decreased oxidative stress. Upon confirming that AG and its components 
activate Nrf2 pathway, we used Nrf2 -/- mice to investigate if the Nrf2 pathway is essential 
for the treatment of colitis. As predicted, AG and its components were not very effective 
in the Nrf2-/- mice as evidenced by the inflammation scores and expression of COX2. 
Though the effects of AG and its components have been diminished considerably, 
there is still a decrease in inflammation with AG treatment of Nrf2 -/- mice. This could be 
due to the effect of p53, which also plays an important role in the activation of antioxidant 
mechanisms like the synthesis of GSH and NADPH generation (39,40). We have 
previously shown that the mechanism of action of AG in the treatment of colitis is p53 
dependent, but the mechanism of HAG is only partially dependent on p53 (10,12). Apart 
from possessing antioxidant properties, Nrf2 has also been shown to negatively regulate 
the expression of pro-inflammatory genes that are induced in M1 mФ (41). This is 
consistent with the decreased expression of ROS, a proinflammatory marker, and could be 
an additional mechanism by which Nrf2 activation helps in the treatment of colitis, that we 
would explore in the future. 
AG, HAG, and PA caused a decrease in the expression of Histone Deacetylase 1 
(HDAC-1) and DNMT-1 in ANA-1 mФ (Figure A1). The increase in Nrf2 shown in Fig. 
8B at the same time as a decrease in HDAC-1 and DNMT-1 is consistent with the 
hypothesis that these enzymes may regulate nrf2 expression. The AG fraction also down-
regulates the expression of miR-142 (Fig. 9) (13), known to target Nrf2 (42), thereby 
suggesting that AG may increase Nrf2 through down-regulation of miR-142. Because Nrf2 
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is involved in colitis and associated colon cancer (32,33,43–45), we believe it would be of 
significance to examine the ability of AG, HAG, and PA to target Nrf2 as a mechanism for 
the protection of colitis and colon cancer. Such studies will not only better elucidate the 
mechanisms by which AG, HAG, and PA work in this disease, but also: (1) identify other 
diseases where Nrf2 is dysregulated that AG, AG-Fraction V, and individual constituents 
may be beneficial [e.g., obesity (46), neurodegenerative diseases (47), vascular diseases 
and aging (48), cardiovascular disease (23), and diabetes (49)]; (2) identify other CAMs or 
small molecules that target Nrf2 that may be beneficial to patients with colitis at a high 
colon cancer risk [e.g., triterpenoids that target Nrf2 also suppress experimental colitis 
(50,51)]; and (3) identify epigenetic biomarkers of Nrf2 regulation and attenuation of 
inflammation. 
CONTRIBUTIONS AND ACKNOWLEDGEMENTS 
This work was supported by National Institutes of Health Center for Colon Cancer 
Research, NCCAM, NIH 2 P01 AT003961- 06A1, and University of South Carolina 
Electronic Research Administration (USCeRA) grant 11110-E193.  
Thanks to Dr. Alexander Chumanevich, Dr. Erin Witalison, and Hossam Tashkandi 
for help with mouse sacrifices. Thanks to Anne Hofseth and Hossam Tashkandi for help 
with immunohistochemistry experiments for Figures 3.2 and 3.4. I thank Ms. Tia Davis at 
the USC Animal Resource Facility for the technical assistance in blood collection. 
72 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: AG, HAG, and PA activate Nrf2 pathway and decrease ROS in vitro. A) 
AG, HAG, and PA induce translocation of Nrf2 into the nucleus. ANA-1 cells were treated 
with AG (100 μg/ml), HAG (100 μg/ml) and PA (1 μM) for 8 hours. Representative images 
of immunofluorescence (n=3). Green arrows indicate nuclei with Nrf2 expression. B) AG, 
HAG, and PA increase the expression of HO-1. Western blot image of ANA-1 cells treated 
with indicated doses of AG, HAG, and PA for 8 hours. C, D) AG (100 μg/ml), HAG (100 
μg/ml) and PA (1 μM) increase the expression of HO-1 (C) and NQO1 (D) in ANA-1 cells. 
RT-qPCR data is cumulative of three separate experiments. E, F) AG, HAG and PA 
activate Nrf2 pathway in HCT-116 cells in the presence of activated mФ. HCT-116 cells 
were pretreated with AG (100 μg/ml), HAG (100 μg/ml) and PA (1 μM) and co-cultured 
with activated ANA-1 (10 ng/ml IFNγ) for 3 hours and separated for qPCR. P-values - * - 
>0.05, ** - >0.005, *** - >0.001, **** - >0.0001. Values represent the mean ± S.D. The 
significance is compared with the DSS only group. G) An oxidative burst in ANA-1 mouse 
mФ is suppressed by pretreatment with AG (100 μg/ml), HAG (100 μg/ml) and PA (1 μM). 
The protocol described in methods.   
73 
 
 
 
 
 
 
Figure 3.2: AG, HAG, and PA activate Nrf2 pathway and decrease ROS in vivo. Effect 
of AG, HAG, and PA on oxidative stress and Nrf2 pathway activation. DSS-induced colitis 
mice were treated with AG (75 mg/kg/day), HAG (75 mg/kg/day), or PA (1 mg/kg/day). 
Colons from these mice were probed for A, B) 4-HNE and C, D) HO-1 to indicate oxidative 
stress and Nrf2 pathway activation, respectively. Values represent the mean ± S.E. N= 8. 
The significance is compared with the DSS only group. P-values - * - >0.05, ** - >0.005. 
A and C are representative images (400X magnification) 
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Figure 3.3 AG, HAG, and PA decrease the CDI in WT mice but not Nrf2 -/- mice. A, 
B) Schematic and groups of the experiment. C) Effect of AG (75 mg/kg/day), HAG (75 
mg/kg/day) and PA (1 mg/kg/day) on the clinical disease index which accounts for weight 
loss, blood in stool and stool consistency. Values represent the mean ± S.E. Significance is 
compared with the DSS only sub-group within WT and Nrf2 -/- groups. P-values - * - 
>0.05, ** - >0.005, *** - >0.001, **** - >0.0001.
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Figure 3.4 AG, HAG, and PA decrease the inflammation in WT mice but not Nrf2 -/- 
mice. Seven-ten mice from each group from Fig 3.3 were euthanized on day 14, and colons 
were harvested. A, B) Effects of AG, HAG, and PA on the colon histology score in the 
acute DSS colitis model. The histology score was determined as discussed in Materials 
and methods. Values represent the mean ± S.E. of the mean. Representative H&E-stained 
colons are shown for each group (A). Sections of the colon were probed for COX2. C) 
Representative images. D) Immunoreactivity score. *Significant difference from the DSS 
group (P values * - >0.05, ** - >0.005, *** - >0.001, **** - >0.0001.).  
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Figure 3.5 AG, HAG, and PA suppress colitis by activation of the Nrf2 pathway. 
Schematic representing the conclusions - oxidative stress is one of the factors that play a 
significant role in the progression of colitis. AG, HAG, and PA activate the transcription 
factor, Nrf2, which in turn activates antioxidant genes that decrease oxidative stress, 
thereby suppressing colitis.
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CHAPTER 4 
 
GENE EXPRESSION PROFILING OF PRIMARY PERITONEAL 
MACROPHAGES TREATED BY AMERICAN GINSENG 
 
ABSTRACT 
 Ginseng has been widely used for its beneficial effects on the general health as well 
as its medicinal properties in the treatment of various ailments. We have previously shown 
that American Ginseng (AG) and its components suppress ulcerative colitis (UC) in mouse, 
underscoring their anti-inflammatory properties, especially in the macrophages (mФ). 
However, the immunostimulatory effects of AG on the innate immune system in the 
absence of inflammation are unclear. MФ play an important role in the initiation of innate 
immune response and activation of the adaptive immune system. To elucidate the various 
key players in the mechanism of action of AG and understand the effects of AG on the 
immune system in a normal state without any inflammation, we conducted a microarray 
experiment using primary peritoneal mФ isolated from mouse and treated with AG or one 
of its derivatives. Microarray analysis revealed that treatment with AG increases the 
expression of various proinflammatory pathways, as seen by the increased expression of 
proinflammatory cytokines like IL6, IL-1α, IL-1β, CXCL1, CXCL3, and CXCL5. This 
suggests that AG and its components stimulate the immune system to prime it against 
possible infection and any other environmental or endogenous insults to the body and this 
property of AG can establish it as an adjuvant therapy.
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4.1 INTRODUCTION 
Korean Ginseng is one of the most-used herbal medicines in the East. More 
recently, other types of ginseng, such as American  Ginseng (AG) have been used as 
alternative medicines worldwide, due to their immunosuppressant, anti-tumorigenic, 
hypoglycemic, antioxidant, and anti-depressant effects (1–3). Furthermore, patients 
suffering from chronic inflammatory diseases use AG in the remission state between the 
flare-ups. Consistent with this, we have previously studied the immunosuppressive effects 
of AG in an inflammatory environment and found that AG and its components (a Hexane 
Fraction of AG, or HAG; and panaxynol, or PA) act as anti-inflammatory agents (4,5)( 
Chapters 2 and 3 of this dissertation). To better understand the underpinnings associated 
with the mechanisms by which AG, HAG, and PA suppress colitis and prevent colon 
cancer, we used gene expression profiling of primary peritoneal mФ (PPMs) by microarray 
and validated the genes with significant increase in expression upon treatment, with qPCR. 
We found that treatment with AG increases the expression of cytokines [interleukin 
(IL)-1α, IL-1β, IL-6, and COX-2] and chemokines [chemokine (C-X-C motif) ligand 
(CXCL)-1, CXCL3 and CXCL5. PA, the bioactive component of AG, also upregulated the 
expression of IL-1α, CXCL1, and CXCL5; while HAG activated IL-1α and CXCL5. These 
results indicate that AG and its components can act as stimulants of a resting immune 
system.  
4.2 MATERIALS AND METHODS 
4.2.1 ISOLATION AND TREATMENT OF PRIMARY PERITONEAL MACROPHAGES 
 Primary peritoneal mФ (PPMs) were harvested from 8-10 week old C57Bl/6 mice. 
Mice were anesthetized and sacrificed by cervical dislocation. 8 ml of phosphate buffer 
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saline (PBS) with 5% fetal bovine serum (FBS) was injected into the peritoneal cavity 
using a 10-gauge syringe, and the peritoneal cavity was massaged to dislodge the immune 
cells in the cavity. The PBS is aspirated back and spun at 1000 RPM for 10 minutes, and 
the pellet is resuspended in RPMI media containing 5% FBS. Cells from one mouse were 
plated in one well in a 6-well dish to be used as a biological replicate. Cells were incubated 
for 2 hours at 370 C and 5% CO2 and supernatant is aspirated, and the wells were washed 
with PBS. The attached cells are mostly mФ and are incubated in whole RPMI media 
containing 50 μg/ml mouse macrophage colony stimulating (mM-CSF) factor overnight. 
The media was aspirated, and the cells were treated with 250 mg/ml AG in whole media 
with mM-CSF. 
4.2.2 RNA ISOLATION AND QUANTIFICATION 
Total RNA was isolated using the Qiagen RNeasy Plus Micro Kit according to the 
manufacturer’s protocol. RNA concentration was measured using Nanodrop 2000. RNA 
quality was assessed using an Agilent 2100 Bioanalyzer, and RNA Integrity Numbers 
ranged from 9.8 to 10.0. 
4.2.3 MICROARRAY ANALYSIS 
Microarray experiments were performed using Affymetrix’s platform. Total RNA 
samples were amplified and biotinylated using GeneChip WT PLUS Reagent Kit 
(Affymetrix, Santa Clara, CA).  Briefly, 100 ng of total RNA per sample was reverse 
transcribed into ds-cDNA using NNN random primers containing a T7 RNA polymerase 
promoter sequence. T7 RNA polymerase was then added to cDNA samples to amplify 
RNA, and then RNA was copied to ss-cDNA and degraded using RNase H. ss-cDNA 
molecules were then fragmented and terminally labeled with biotin. Amplified and labeled 
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samples were hybridized to MoGene-2_0-st (Affymetrix, Santa Clara, CA) for 16 h at 45°C 
using a GeneChip Hybridization Oven 640 and a GeneChip Hybridization, Wash, and Stain 
Kit (Affymetrix, Santa Clara, CA).  Hybridized arrays were washed and stained using 
GeneChip Fluidics Stations 450 (Affymetrix, Santa Clara, CA). Arrays (6 total) were then 
scanned using a GeneChip Scanner 3000 7G system and computer workstation equipped 
with GeneChip Command Console 4.0 software (Affymetrix, Santa Clara, CA).  
4.2.4 REVERSE TRANSCRIPTASE-QUANTITATIVE POLYMERASE CHAIN REACTION (RT-QPCR) 
The cells were lysed using Trizol and RNA was isolated using the RNeasy mini kit 
(Cat # 74104; Qiagen, Hilden, Germany) according to the instructions. RNA 
concentrations were measured using NanoDrop 2000 spectrophotometer (Thermo Fisher 
Scientific). 1μg of RNA was used for cDNA synthesis using iScript cDNA synthesis kit 
(cat # 1708890; Bio-rad, Hercules, CA). The final product was diluted 1:10 for qPCR. 
qPCR was performed using iTaq™ Universal SYBR® Green Supermix (cat #1725121; 
Bio-rad, Hercules, CA). The list of primers used is as follows in the order forward then 
reverse in 5`-3` orientation. – HO-1: AAGCCGAGAATGCTGAGTTCA, 
GCCGTGTAGATATGGTACAAGGA; NQO1: AGGATGGGAGGTACTCGAATC, 
AGGCGTCCTTCCTTATATGCTA; GAPDH: AGGTCGGTGTGAACGGATTTG, 
TGTAGACCATGTAGTTGAGGTCA., IL6: CCAAGAGGTGAGTGCTTCCC, 
CTGTTGTTCAGACTCTCTCCCT; CXCL3: TAACCCTCATCAGAGTACTGGC, 
GAAAGAGGCTCCAGGTAGGG; CXCL1: TGAGCTGCGCTGTCAGTGCCT, 
AGAAGCCAGCGTTCACCAGA; CXCL5: GCATTTCTGTTGCTGTTCACGCTG, 
CCTCCTTCTGGTTTTTCAGTTTAGC; IL-1b, CCTTCCAGGATGAGGACATGA, 
TGAGTCACAGAGGATGGGCTC; IL-1a: CGAAGACTACAGTTCTGCCATT, 
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GACGTTTCAGAGGTTCTCAGAG; Ptgs2: TGCCTGGTCTGATGATGTATG, 
GCCCTTCACGTTATTGCAGATG. qPCR was performed on CFX384 Touch™ Real-
Time PCR Detection System (cat # 1855485; Bio-rad, Hercules, CA). 
4.2.5 STATISTICAL ANALYSIS 
Following completion of array scans, probe cell intensity (CEL) files were imported 
into Expression Console Software (Affymetrix, Santa Clara, CA) and processed at the 
gene-level using the Robust Multichip Analysis (RMA) algorithm to generate CHP files. 
After confirming data quality within Expression Console, CHP files containing log2 
expression signals for each probe were then imported into Transcriptome Analysis Console 
Software version 4.0 (Affymetrix, Santa Clara, CA) to analyze cell type-specific 
transcriptional responses using one-way between-subject analysis of variance (ANOVA). 
A p-value of 0.05 and a fold change of 2.0 was used as cutoff parameters. Subsequently, 
pathway analysis of the differentially expressed genes was performed using Ingenuity 
Pathway Analysis software (IPA) (Qiagen, Hilden, Germany).  
qPCR data is expressed as a mean ± standard error of the mean. Mean differences 
between the groups were compared by one-way analysis of variance (ANOVA), followed 
by Dunnett’s multiple comparison tests. A p-value of ≤ 0.05 was chosen for significance. 
4.3 RESULTS 
4.3.1 GENE EXPRESSION PROFILE OF PRIMARY PERITONEAL MACROPHAGES TREATED WITH 
AMERICAN GINSENG 
 PPM isolated from C57B/6 mice were cultured for a day and treated with 250 
mg/ml of AG for 8 hours in quadruplicates. RNA collected from these samples was 
analyzed for concentration, purity, and integrity, upon which three biological replicates for 
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each condition were selected for microarray analysis. We determined the treatment doses 
prior to microarray to ensure that these concentrations would cause a change in gene 
expression. We accomplished this by probing PPMs treated with various doses of AG, 
HAG, and PA, for HO-1, a known target of all three compounds. We compared the treated 
and untreated samples using Kruskal-Wallis statistics with Benjamini-Hochberg multiple 
testing corrections at a fold-change cut-off of 2 and a p-value of 0.05. The number of 
differentially expressed genes with at least 2-fold change were identified. 32 genes were 
upregulated, and 20 genes were downregulated upon treatment with AG when compared 
to the vehicle group (Figure 4.1A). However, HAG only had one gene that showed more 
than 2-fold change in expression and PA did not have any viable target genes that had any 
change in expression profile (Figure 4.1A). There was only one common target for AG and 
HAG which was NQO1 (Figure 4.1B). Surprisingly, a number of pro-inflammatory genes 
were activated by AG. Of these, the expression of IL-6 was elevated the most with the AG 
treatment with a fold change of 5.87 and a p-value of 0.0005. Scatter plot of differentially 
expressed genes and hierarchal clustering of intensities of mRNA expression are shown in 
Figures - 4.2 and 4.3 respectively. The list of genes that are differentially expressed with 
AG treatment is presented in Table 4.1. 
4.3.2 INGENUITY PATHWAY ANALYSIS (IPA) OF MICROARRAY RESULTS 
 IPA shows distinct activation of triggering receptor expressed on myeloid cells 
(TREM1) signaling pathway, with the target genes CXCL3, IL1B, IL6, NLRP3, and CSF2, 
with the first three genes showing more than 2.5 fold increase in gene expression (Figure 
4.4). Activation of the TREM1 receptor that is expressed on mФ and neutrophils plays an 
important role in systemic infection by causing a cascade of events that result in cytokine 
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production. The top- hits like CXCL2, CXCL3, PTGS2, IL1A, IL1B, and IL6 are also 
involved in toll-like receptor (TLR) signaling, especially TLR2, TLR3, TLR4, TLR5, and 
TLR9. The target genes identified here are upstream regulators of various proinflammatory 
genes and play an important role in the recruitment, activation, and migration of 
phagocytes, in this case, mФ. 
4.3.3 REVERSE TRANSCRIPTASE-QUANTITATIVE POLYMERASE CHAIN REACTION (RT-QPCR) 
ANALYSIS OF SELECTED TARGET GENES  
 To confirm the differential expression of the targets identified in the microarray 
analysis, we conducted the RT-qPCR analysis. Since HAG or PA did not yield multiple 
results, we validated the targets of AG using qPCR and compared the gene expression in 
the samples from HAG and PA. This analysis confirmed the activation of proinflammatory 
cytokines by AG. We saw that, while some of AG's targets only showed increased 
expression upon AG treatment, e.g., IL6, IL-1β, and CXCL3 (Figure 4.4A, B, C), others 
showed changed gene expression profiles in HAG and/or PA. IL-1α and CXCL1 showed 
increased expression in both HAG and PA-treated cells (Figures 4.4 D, E), while CXCL5 
expression was increased in PA but not HAG (Figure 4.4F).  
PTGS2 or COX2, one of the potential targets was not validated by qPCR (Figure 
4.4 G). We also examined the expression of NQO1 and HO-1 as they have previously been 
shown to be upregulated in AG treatments.  NQO1 was also one of the targets of both AG 
and HAG that manifested in the microarray analysis. However, there was no change in the 
expression with any of the treatments when validated with qPCR. HO-1, on the other hand, 
showed increased expression with AG, HAG, or PA treatments, even though it was not one 
of the genes with changed expression profile in the microarray (Figure 4.4 I). 
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4.4 DISCUSSION 
 AG has been used as an anti-inflammatory agent for the treatment of UC in our 
previous studies (6,7), and we found that PA, a polyacetylene in AG specifically targets 
mФ for DNA damage and apoptosis. PA was the most abundant compound in the hexane 
fraction of AG (HAG), the most potent of the various fractions of AG (5). To further 
understand the mechanisms of action of AG, HAG, and PA in the treatment of colitis and 
prevention of colon cancer, we profiled the gene expression patterns in PPMs using 
microarray analysis.  
 Curiously, treatment with AG resulted in the upregulation of a number of cytokines 
and chemokines, which is in contrast with their anti-inflammatory properties. 
Unfortunately, microarray analysis of treatment with HAG only yielded one gene with an 
at least 2-fold change in expression and treatment with PA did not produce any valid 
targets, even though we standardized the dose and treatment times prior to the microarray. 
However, when we followed up on the top-hits with AG treatment using qPCR in the 
samples treated with all three compounds to identify any common targets and targets 
unique to AG treatment, we found that HAG and PA also increased the expression of some 
of the cytokines and chemokines. This discrepancy in results could be due to the fact that 
qPCR is more sensitive and quantitative than microarray.  
This immunostimulatory effect of AG could indicate that AG can boost the innate 
immune system to prime it against infections and other environmental insults. This 
property of AG can also be exploited in cancer immunotherapy for use as an adjuvant. The 
immune system is comprised of two separate and interacting components – innate and 
adaptive immunity. The innate immune system forms the first barrier of defense against 
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the infections and includes physical barriers like skin and mucous membranes; phagocytic 
immune cells like mФ and natural killer cells; inflammatory mediators like eosinophil 
granules; and cytokines (8,9). These components recognize infection and initiate primary 
reactions to prevent and eliminate an infection. Toll-like receptors (TLRs) are pattern 
recognition receptors (PPRs) that are present on the myeloid cells like mФ and dendritic 
cells, recognize pathogen-associated molecular patterns (PAMPs) on the invading 
pathogens and danger associated molecular patterns (DAMPs) from tissue injury, and 
initiate an appropriate immune response (10–12). This immunological signaling is finely 
balanced. Lack of appropriate regulation of TLRs can result in chronic inflammation 
(13,14). Conversely, the decreased response in early stages of infection or neoplastic 
transformation can have adverse effects like worsened infection or tumor formation (15). 
MФ form an important part of the innate immune system and are activated by binding of 
ligands to surface TLRs like TLR4 (16–18). In the presence of an impending infection, mФ 
are activated to phagocytose the pathogens and produce proinflammatory cytokines like 
TNFα, and inflammatory mediators like nitric oxide (NO) and H2O2 (19). Plant extracts 
have been previously shown to modulate the TLR activation and function (20–23).   
Among the predicted upstream regulators of the top genes, TLR4 appears to be of 
importance. It has been previously shown that plant extracts can initiate an innate immune 
response by activating TLRs, particularly TLR4 (20–22). This can result in the activation 
of transcription factors like NF-κB and AP-1, which in turn increase the production of 
proinflammatory mediators like TNF-α, IL-6, IL-1, and COX2 (24). The activation of 
proinflammatory cytokines by AG could be a result of TLR4 activation. TLR agonists are 
currently being investigated in the development of immunotherapy strategies for the 
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treatment of cancer. TLR ligands have been previously used as adjuvants in the 
development of vaccines in cancer immunotherapy (25–27). For example, 
Monophosphoryl lipid A (MPL), a TLR4 ligand is being tested as an adjuvant to vaccines 
against colorectal carcinoma, melanoma, glioma, etc., to initiate tumor-specific immunity 
in response to vaccination (28). Adjuvants can decrease the immunotolerance in the tumor 
microenvironment and aid in the initiation of anti-tumor response(25,27). If AG is 
established as a TLR ligand, it can be used as an adjuvant with vaccines for cancer and 
infectious diseases. 
 We used PPMs, which have not been polarized to either M1 or M2 type in our 
study. For future studies, we will confirm the findings above, then compare the effects of 
AG and its components between the different types of mФ, in vivo and in vitro by 
examining the expression patterns of proinflammatory cytokines. We will also examine the 
effects of AG on dendritic cells which along with mФ are the sentinels of innate immune 
system and function via TLR signaling. These studies will provide an insight into the 
divergent effects of AG, especially in the treatment of UC. UC is a chronic disease with 
periods of remission alternated with a period of flare-ups. It is important to have active 
immune system in the remission periods to enable the body to fight the infections. The 
property of AG to modulate the immune system will be especially appreciated in these 
periods of remission to ensure the patient is not susceptible to infections. 
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Figure 4.1 Gene expression profiling of primary peritoneal macrophages treated with 
AG, HAG, and PA. A) Summary of the microarray analysis of PPMs treated with AG 
(100μg/ml), HAG (100μg/ml) and PA (1μM) to address the number of genes that have been 
differentially regulated. B) Venn diagram representing common targets that manifested in 
microarray analysis.
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Figure 4.2 Representation of differential gene expression with AG treatment when 
compared to the control group. Scatter plot of mRNA expression determined by mRNA 
microarray analysis. The expression profile of ~35,000 mRNAs on a log2 scale with AG 
treatment and control group is plotted. Red and green dots represent the mRNAs that were 
significantly (P < 0.05 and 1.5 fold-change cut-off) up-regulated and down-regulated, 
respectively, in AG group. Grey dots represent a lack of differential expression.
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Table 4.1 List of differentially expressing genes with AG treatment  
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Figure 4.3 Hierarchal clustering of replicates. Hierarchical clustering of samples based 
on differentially expressed genes with at least 2-fold change and controlled by false 
discovery rate of 0.1, from AG treated vs. control groups. In the clustering heat map, red 
indicates upregulation while green indicates downregulation. In the sample clustering 
dendrogram, red indicates AG samples while blue indicates control samples. The intensity 
of expression is indicated by blue (low) and red (high), with white being medium.
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Figure 4.4 Activation of TREM pathway from IPA. TREM pathway showed activation 
in IPA. TREM pathway involving TLR4 is upstream of the cytokines and chemokines that 
were upregulated by AG.One of the TREM pathways, involving proinflammatory response 
is highlighted here. 
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Figure 4.5 Validation of differentially expressed genes by qPCR. Targets identified by 
microarray analysis of AG treated mФ was validated in all three treatments. A, B, C) Genes 
that were validated only in AG. D, E, F) Genes also verified in HAG and or PA. G, H) 
Identified targets of AG that were not validated by qPCR. Fold changes presented are 
cumulative mean of three separate experiments. 
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CHAPTER 5 
CONCLUSION AND FUTURE DIRECTIONS 
 
5.1 SUMMARY AND CONCLUSIONS 
 American Ginseng (AG), and one of its fractions, HAG, have been shown to be 
effective in the treatment of colitis and colon cancer in mice. In chapter 2, we aimed to 
identify the bioactive component of AG. We used bioassay-guided fractionation to isolate 
various sub-fractions of HAG and test their ability to suppress the expression of iNOS, an 
inflammatory marker. PA was the most abundant compound in the fraction with the anti-
inflammatory potential and was further studied as a potential treatment for colitis.  PA 
successfully suppressed DSS-induced colitis in the mouse. We also found that PA 
selectively targets macrophages (mФ) for apoptosis in vivo and in vitro. Additionally, PA 
was more effective than clodronate, a compound that specifically targets mФ and did not 
enhance the effect of clodronate in the treatment of colitis. However, PA was not effective 
in the prevention of colitis. 
 In chapter 3, we explore the mechanism of action of AG, HAG, and PA. We have 
previously seen that AG decreases oxidative stress in proinflammatory mФ. Here we see 
that HAG and PA decrease the production of ROS and thereby oxidative stress in the mФ. 
AG, HAG, and PA also activate the Nrf2 dependent antioxidant pathway in both ANA-1 
and HCT-116 cells that were co-cultured with ANA-1 cells. These components also 
activate Nrf2 pathway and decrease oxidative stress in vivo in DSS-induced colitis colons. 
In the absence of Nrf2, AG and its components are not very effective in the treatment of 
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colitis as seen by the comparison between wild-type and Nrf2 knockout mice. However, 
even in the absence of Nrf2, AG slightly decreased the extent of colitis. This could be due 
to the role that p53 plays in the treatment of colitis by AG. 
 In chapter 5, we wanted to further explore the effect of AG on the innate immune 
system. We conducted a gene expression profiling of primary peritoneal mФ treated with 
AG using microarray. Surprisingly, the gene expression profile indicated that AG increased 
the expression of proinflammatory cytokines like IL-1α, IL-1β, and IL-6 and chemokines 
like CXCL2, CXCL3, and CXCL5. We confirmed the top hits of microarray using RT-
qPCR in AG samples, as well as HAG and PA samples. The pathway analysis of these 
targets and other genes with increased expression indicated that proinflammatory pathways 
like NFκb and TNF-α pathways could be activated. This contradicts with the anti-
inflammatory activity of AG in the treatment of inflammatory diseases. However, this 
indicates that AG can act as an immune boost to prime the immune system to fight potential 
infections 
 From the findings in this dissertation, we have identified the bioactive component 
of AG and gained insights into the mechanism of action of AG and its components. PA 
treats colitis in mice by the selective targeting of mФ for DNA damage and apoptosis. 
Activation of the Nrf2 antioxidant mechanism is the key to the mechanism of action of AG, 
HAG, and PA. Activation of proinflammatory pathways by AG in a normal state provides 
insight into the immunomodulatory effects of AG and provides a segue for future 
investigations. 
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5.2 FUTURE DIRECTIONS 
To further the outcomes from chapter 4, we will compare the expression of 
proinflammatory cytokines and activation of proinflammatory pathways between activated 
and non-activated mФ in vitro using primary cells and established cell lines. In vivo, we 
will study the effect of treatment with AG on the innate immunity in the absence of an 
infection. This will help us understand its effectiveness in the prevention of infections. 
We would like to explore further, the mechanism by which PA targets mФ. Since 
PA causes DNA damage, we will concentrate on DNA repair pathways that could be 
impaired in the mФ, leading to apoptosis. Identifying the DNA repair mechanism and its 
status in non-macrophage cell lines would provide understanding into the specificity of PA 
in targeting the mФ.  
We will test the toxicity and side effects of PA in the organs collected during our 
in vivo experiments (e.g., Liver: Serum Bilirubin, Serum Albumin, ALT [Alanine amino 
transferase], and AST [Aspartate amino transferase] test; Kidney: Urinalysis, Blood Urea 
nitrogen). Upon validation of PA as a safe and effective treatment for colitis in classic 
models of IBD, we hope to explore its potential as a treatment for other inflammatory 
diseases like rheumatoid arthritis, lupus, and psoriasis, improving the quality of life for 
millions of people. 
 Since colitis increases the risk of colitis-associated colon cancer, we conducted 
preliminary studies to determine the effectiveness of PA in the prevention of colon cancer. 
These studies conducted with AOM-DSS mouse model showed that PA-treated mice had 
smaller tumors (> 2mm). Preliminary data also indicates that PA decreases the expression 
of DNMT1 and HDAC in activated ANA-1 cells, indicating its role in epigenetic regulation 
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(Figure A.1). We will explore the possibility of PA as a chemopreventive agent for colon 
cancer using various colon cancer mouse models with an emphasis on epigenetics. 
We will also study other components of AG in the hexane fraction, mainly 
polyacetylenes like Panaxydol and Panaxadiol. 
106 
 
REFERENCES  
1. Nathan, C. Points of control in inflammation. Nature 420, 846–852 (2002). 
2. Green, S. J., Mellouk, S., Hoffman, S. L., Meltzer, M. S. & Nacy, C. A. Cellular 
mechanisms of nonspecific immunity to intracellular infection: cytokine-induced 
synthesis of toxic nitrogen oxides from L-arginine by macrophages and hepatocytes. 
Immunol. Lett. 25, 15–9 (1990). 
3. Vane, J. R. et al. Inducible isoforms of cyclooxygenase and nitric-oxide synthase in 
inflammation. Proc. Natl. Acad. Sci. U. S. A. 91, 2046–50 (1994). 
4. Seibert, K. & Masferrer, J. L. Role of inducible cyclooxygenase (COX-2) in 
inflammation. Receptor 4, 17–23 (1994). 
5. Hussain, S. P., Hofseth, L. J. & Harris, C. C. Radical causes of cancer. Nat. Rev. 
Cancer 3, 276–285 (2003). 
6. Kim, E. R. & Chang, D. K. Colorectal cancer in inflammatory bowel disease: the 
risk, pathogenesis, prevention and diagnosis. World J. Gastroenterol. 20, 9872–81 
(2014). 
7. Rao, C. V., Rivenson, A., Simi, B. & Reddy, B. S. Chemoprevention of Colon 
Carcinogenesis by Dietary Curcumin, a Naturally Occurring Plant Phenolic 
Compound. Cancer Res. 55, (1995). 
8. Middleton, E., Kandaswami, C. & Theoharides, T. C. The Effects of Plant 
Flavonoids on Mammalian Cells:Implications for Inflammation, Heart Disease, and 
Cancer. Pharmacol. Rev. 52, (2000). 
9. Jang, M. et al. Cancer Chemopreventive Activity of Resveratrol, a Natural Product 
Derived from Grapes. Science (80-. ). 275, (1997). 
10. Cosnes, J., Gower-Rousseau, C., Seksik, P. & Cortot, A. Epidemiology and natural 
history of inflammatory bowel diseases. Gastroenterology 140, 1785–94 (2011). 
11. Sartor, R. B. Current concepts of the etiology and pathogenesis of ulcerative colitis 
and Crohn’s disease. Gastroenterol. Clin. North Am. 24, 475–507 (1995). 
12. Ford, A. C., Moayyedi, P. & Hanauer, S. B. Ulcerative colitis. BMJ 346, f432 
(2013). 
13. Ordás, I., Eckmann, L., Talamini, M., Baumgart, D. C. & Sandborn, W. J. Ulcerative 
colitis. Lancet 380, 1606–1619 (2012).
107 
 
14. D’Haens, G. et al. A review of activity indices and efficacy end points for clinical 
trials of medical therapy in adults with ulcerative colitis. Gastroenterology 132, 
763–86 (2007). 
15. Kwak, M.-K. & Kensler, T. W. Targeting NRF2 signaling for cancer 
chemoprevention. Toxicol. Appl. Pharmacol. 244, 66–76 (2010). 
16. Papalois, A. et al. Chios mastic fractions in experimental colitis: implication of the 
nuclear factor κB pathway in cultured HT29 cells. J. Med. Food 15, 974–83 (2012). 
17. Tomasello, E. & Bedoui, S. Intestinal innate immune cells in gut homeostasis and 
immunosurveillance. Immunol. Cell Biol. 91, 201–203 (2013). 
18. Peterson, L. W. & Artis, D. Intestinal epithelial cells: regulators of barrier function 
and immune homeostasis. Nat. Rev. Immunol. 14, 141–153 (2014). 
19. Akira, S., Uematsu, S. & Takeuchi, O. Pathogen Recognition and Innate Immunity. 
Cell 124, 783–801 (2006). 
20. Iwasaki, A. & Medzhitov, R. Toll-like receptor control of the adaptive immune 
responses. Nat. Immunol. 5, 987–995 (2004). 
21. Garrett, W. S., Gordon, J. I. & Glimcher, L. H. Homeostasis and inflammation in 
the intestine. Cell 140, 859–70 (2010). 
22. Geissmann, F. et al. Development of Monocytes, Macrophages, and Dendritic Cells. 
Science (80-. ). 327, (2010). 
23. Forkner, C. E. THE ORIGIN OF MONOCYTES IN CERTAIN LYMPH NODES 
AND THEIR GENETIC RELATION TO OTHER CONNECTIVE TISSUE 
CELLS. J. Exp. Med. 52, 385–404 (1930). 
24. Netea, M. G. et al. Interleukin-32 induces the differentiation of monocytes into 
macrophage-like cells. Proc. Natl. Acad. Sci. U. S. A. 105, 3515–20 (2008). 
25. Schenk, M. et al. Interleukin-1β triggers the differentiation of macrophages with 
enhanced capacity to present mycobacterial antigen to T cells. Immunology 141, 
174–180 (2014). 
26. Mitani, H. et al. Activity of interleukin 6 in the differentiation of monocytes to 
macrophages and dendritic cells. Br. J. Haematol. 109, 288–295 (2000). 
27. Gordon, S. The macrophage: Past, present and future. Eur. J. Immunol. 37, S9–S17 
(2007). 
28. Mills, C. D. Anatomy of a discovery: m1 and m2 macrophages. Front. Immunol. 6, 
212 (2015). 
29. Mills, C. D. & Ley, K. M1 and M2 Macrophages: The Chicken and the Egg of 
Immunity. J. Innate Immun. 6, 716–726 (2014). 
108 
 
30. Martinez, F. O. & Gordon, S. The M1 and M2 paradigm of macrophage activation: 
time for reassessment. F1000Prime Rep. 6, 1–13 (2014). 
31. Arango Duque, G. & Descoteaux, A. Macrophage cytokines: involvement in 
immunity and infectious diseases. Front. Immunol. 5, 491 (2014). 
32. Ravi, S., Mitchell, T., Kramer, P., Chacko, B. & Darley-Usmar, V. M. Mitochondria 
in monocytes and macrophages-implications for translational and basic research. 
Int. J. Biochem. Cell Biol. 53, 202–207 (2014). 
33. Liu, Y.-C., Zou, X.-B., Chai, Y.-F. & Yao, Y.-M. Macrophage Polarization in 
Inflammatory Diseases. Int. J. Biol. Sci. 10, 520–529 (2014). 
34. Ma, X. et al. Regulation of IL-10 and IL-12 production and function in macrophages 
and dendritic cells. F1000Research 4, (2015). 
35. Murray, P. J. & Wynn, T. A. Protective and pathogenic functions of macrophage 
subsets. Nat. Rev. Immunol. 11, 723–737 (2011). 
36. Elliott, T. R. et al. Lamina propria macrophage phenotypes in relation to Escherichia 
coli in Crohn’s disease. BMC Gastroenterol. 15, 75 (2015). 
37. Steinbach, E. C. & Plevy, S. E. The role of macrophages and dendritic cells in the 
initiation of inflammation in IBD. doi:10.1097/MIB.0b013e3182a69dca 
38. Bain, C. C. & Mowat, A. M. Macrophages in intestinal homeostasis and 
inflammation. Immunol. Rev. 260, 102–17 (2014). 
39. Sohn, J. J. et al. Macrophages, nitric oxide and microRNAs are associated with DNA 
damage response pathway and senescence in inflammatory bowel disease. PLoS 
One 7, e44156 (2012). 
40. Birben, E., Sahiner, U. M., Sackesen, C., Erzurum, S. & Kalayci, O. Oxidative stress 
and antioxidant defense. World Allergy Organ. J. 5, 9–19 (2012). 
41. Mittal, M., Siddiqui, M. R., Tran, K., Reddy, S. P. & Malik, A. B. Reactive oxygen 
species in inflammation and tissue injury. Antioxid. Redox Signal. 20, 1126–67 
(2014). 
42. Muralidharan, S. & Mandrekar, P. Cellular stress response and innate immune 
signaling: integrating pathways in host defense and inflammation. J. Leukoc. Biol. 
94, 1167–84 (2013). 
43. Dröse, S. & Brandt, U. in Advances in experimental medicine and biology 748, 145–
169 (2012). 
44. Reuter, S., Gupta, S. C., Chaturvedi, M. M. & Aggarwal, B. B. Oxidative stress, 
inflammation, and cancer: how are they linked? Free Radic. Biol. Med. 49, 1603–
16 (2010). 
45. Wink, D. A. et al. Nitric oxide and redox mechanisms in the immune response. J. 
109 
 
Leukoc. Biol. 89, 873–91 (2011). 
46. Zhong, H. & Yin, H. Role of lipid peroxidation derived 4-hydroxynonenal (4-HNE) 
in cancer: focusing on mitochondria. Redox Biol. 4, 193–9 (2015). 
47. Florence, T. M. The production of hydroxyl radical from hydrogen peroxide. J. 
Inorg. Biochem. 22, 221–230 (1984). 
48. McCord, J. M. & Fridovich, I. Superoxide Dismutases: You’ve Come a Long Way, 
Baby. Antioxid. Redox Signal. 20, 1548–1549 (2014). 
49. Marí, M., Morales, A., Colell, A., García-Ruiz, C. & Fernández-Checa, J. C. 
Mitochondrial glutathione, a key survival antioxidant. Antioxid. Redox Signal. 11, 
2685–700 (2009). 
50. Espinosa-Diez, C. et al. Antioxidant responses and cellular adjustments to oxidative 
stress. Redox Biol. 6, 183–97 (2015). 
51. Javeed, S. et al. Review Nrf2: A MASTER REGULATOR OF CELLULAR 
DEFENSE MECHANISM AND A NOVEL THERAPEUTIC FACTOR. J. 
Biotechnol 14, 121–126 (2017). 
52. Li, L. et al. Nrf2/ARE pathway activation, HO-1 and NQO1 induction by 
polychlorinated biphenyl quinone is associated with reactive oxygen species and 
PI3K/AKT signaling. Chem. Biol. Interact. 209, 56–67 (2014). 
53. TANIGAWA, S., FUJII, M. & HOU, D. Action of Nrf2 and Keap1 in ARE-
mediated NQO1 expression by quercetin. Free Radic. Biol. Med. 42, 1690–1703 
(2007). 
54. Loboda, A., Damulewicz, M., Pyza, E., Jozkowicz, A. & Dulak, J. Role of Nrf2/HO-
1 system in development, oxidative stress response and diseases: an evolutionarily 
conserved mechanism. Cell. Mol. Life Sci. 73, 3221–47 (2016). 
55. Nguyen, T., Nioi, P. & Pickett, C. B. The Nrf2-antioxidant response element 
signaling pathway and its activation by oxidative stress. J. Biol. Chem. 284, 13291–
5 (2009). 
56. Kansanen, E., Kuosmanen, S. M., Leinonen, H. & Levonen, A.-L. The Keap1-Nrf2 
pathway: Mechanisms of activation and dysregulation in cancer. Redox Biol. 1, 45–
49 (2013). 
57. Keum, Y.-S. Regulation of Nrf2-Mediated Phase II Detoxification and Anti-oxidant 
Genes. Biomol. Ther. (Seoul). 20, 144–51 (2012). 
58. Thimmulappa, R. K. et al. Nrf2 is a critical regulator of the innate immune response 
and survival during experimental sepsis. J. Clin. Invest. 116, 984–995 (2006). 
59. Ishii, Y. et al. Transcription factor Nrf2 plays a pivotal role in protection against 
elastase-induced pulmonary inflammation and emphysema. J. Immunol. 175, 6968–
110 
 
75 (2005). 
60. Iizuka, T. et al. Nrf2-deficient mice are highly susceptible to cigarette smoke-
induced emphysema. Genes to Cells 10, 1113–1125 (2005). 
61. Itoh, K. et al. Transcription factor Nrf2 regulates inflammation by mediating the 
effect of 15-deoxy-Delta(12,14)-prostaglandin j(2). Mol. Cell. Biol. 24, 36–45 
(2004). 
62. Venci, J. V. & Gandhi, M. A. Dimethyl Fumarate (Tecfidera). Ann. Pharmacother. 
47, 1697–1702 (2013). 
63. Russell, R. I. Non-steroidal anti-inflammatory drugs and gastrointestinal damage-
problems and solutions. Postgrad. Med. J. 77, 82–8 (2001). 
64. Tanaka, A., Araki, H., Komoike, Y., Hase, S. & Takeuchi, K. Inhibition of both 
COX-1 and COX-2 is required for development of gastric damage in response to 
nonsteroidal antiinflammatory drugs. J. Physiol. 95, 21–27 (2001). 
65. Feagan, B. G. & MacDonald, J. K. in Cochrane Database of Systematic Reviews 
(ed. Feagan, B. G.) 10, CD000543 (John Wiley & Sons, Ltd, 2012). 
66. Kurmaeva, E. et al. T cell-associated α4β7 but not α4β1 integrin is required for the 
induction and perpetuation of chronic colitis. Mucosal Immunol. 7, 1354–1365 
(2014). 
67. Lok, K.-H. et al. Epidemiology and clinical characteristics of ulcerative colitis in 
Chinese population: Experience from a single center in Hong Kong. J. 
Gastroenterol. Hepatol. 23, 406–410 (2008). 
68. Hilsden, R. J., Verhoef, M. J., Best, A. & Pocobelli, G. Complementary and 
Alternative Medicine Use by Canadian Patients With Inflammatory Bowel Disease: 
Results from a National Survey. doi:10.1016/S0002-9270(03)00301-0 
69. Hou, J. P. The chemical constituents of ginseng plants. Comp. Med. East West 5, 
123–45 (1977). 
70. CHOI, K. Botanical characteristics, pharmacological effects and medicinal 
components of Korean Panax ginseng C A Meyer. Acta Pharmacol. Sin. 29, 1109–
1118 (2008). 
71. Yuan, C.-S., Wang, C.-Z., Wicks, S. M. & Qi, L.-W. Chemical and pharmacological 
studies of saponins with a focus on American ginseng. J. Ginseng Res. 34, 160–7 
(2010). 
72. Xie, G. et al. Metabonomic Profiling Reveals Cancer Chemopreventive Effects of 
American Ginseng on Colon Carcinogenesis in Apc  Min/+  Mice. J. Proteome Res. 
14, 3336–3347 (2015). 
73. JIAN-LI GAO, G.-Y. L. B.-C. H. B.-Q. Z. H. Z. N. W. C.-Z. W. W. D. C.-S. Y. T.-
111 
 
C. H. Ginseng saponin metabolite 20(S)-protopanaxadiol inhibits tumor growth by 
targeting multiple cancer signaling pathways. Oncol. Rep. 30, 292 (2013). 
74. Li, B., Wang, C.-Z., He, T.-C., Yuan, C.-S. & Du, W. Antioxidants potentiate 
American ginseng-induced killing of colorectal cancer cells. Cancer Lett. 289, 62–
70 (2010). 
75. Zhang, Z. et al. TRAIL pathway is associated with inhibition of colon cancer by 
protopanaxadiol. J. Pharmacol. Sci. 127, 83–91 (2015). 
76. Jin, Y. et al. American ginseng suppresses colitis through p53-mediated apoptosis 
of inflammatory cells. Cancer Prev. Res. (Phila). 3, 339–47 (2010). 
77. Cui, X. et al. Mechanistic insight into the ability of American ginseng to suppress 
colon cancer associated with colitis. Carcinogenesis 31, 1734–1741 (2010). 
78. Poudyal, D. et al. A key role of microRNA-29b for the suppression of colon cancer 
cell migration by American ginseng. PLoS One 8, e75034 (2013). 
79. Poudyal, D. et al. A Limited Role of p53 on the Ability of a Hexane Fraction of 
American Ginseng to Suppress Mouse Colitis. J. Biomed. Biotechnol. 2012, 785739 
(2012). 
80. Poudyal, D. et al. A hexane fraction of American ginseng suppresses mouse colitis 
and associated colon cancer: Anti-inflammatory and proapoptotic mechanisms. 
Cancer Prev. Res. 5, 685–696 (2012). 
81. Jin, Y. et al. American ginseng suppresses inflammation and DNA damage 
associated with mouse colitis. Carcinogenesis 29, 2351–2359 (2008). 
82. Dougherty, U. et al. American ginseng suppresses Western diet-promoted 
tumorigenesis in model of inflammation-associated colon cancer: role of EGFR. 
BMC Complement. Altern. Med. 11, 111 (2011). 
83. Yu, C. et al. American ginseng significantly reduced the progression of high-fat-
diet-enhanced colon carcinogenesis in Apc (Min/+) mice. J. Ginseng Res. 39, 230–
7 (2015). 
84. Wang, C.-Z. et al. American Ginseng Attenuates Colitis Associated Colon 
Carcinogenesis in Mice: Impact on Gut Microbiota and Metabolomics. Cancer Prev. 
Res. (Phila). (2016). doi:10.1158/1940-6207.CAPR-15-0372 
85. Poudyal, D. et al. A Hexane Fraction of American Ginseng Suppresses Mouse 
Colitis and Associated Colon Cancer: Anti-inflammatory and Proapoptotic 
Mechanisms. Cancer Prev. Res. 5, (2012). 
86. Qu, C. et al. Identifying panaxynol, a natural activator of nuclear factor erythroid-2 
related factor 2 (Nrf2) from American ginseng as a suppressor of inflamed 
macrophage-induced cardiomyocyte hypertrophy. J. Ethnopharmacol. 168, 326–36 
(2015). 
112 
 
87. Poudyal, D. et al. A hexane fraction of American ginseng suppresses mouse colitis 
and associated colon cancer: Anti-inflammatory and proapoptotic mechanisms. 
Cancer Prev. Res. 5, 685–696 (2012). 
88. Christensen, L. P. Aliphatic C(17)-polyacetylenes of the falcarinol type as potential 
health promoting compounds in food plants of the Apiaceae family. Recent Pat. 
Food. Nutr. Agric. 3, 64–77 (2011). 
89. Paulsen, E., Christensen, L. P. & Andersen, K. E. Dermatitis from common ivy 
(Hedera helix L. subsp. helix) in Europe: past, present, and future. Contact 
Dermatitis 62, 201–209 (2010). 
90. Block, G., Patterson, B. & Subar, A. Fruit, vegetables, and cancer prevention: A 
review of the epidemiological evidence. Nutr. Cancer 18, 1–29 (1992). 
91. Matsunaga, H., Katano, M., Yamamoto, H., Mori, M. & Takata, K. Studies on the 
panaxytriol of Panax ginseng C. A. Meyer. Isolation, determination and antitumor 
activity. Chem. Pharm. Bull. (Tokyo). 37, 1279–81 (1989). 
92. Matsunaga, H. et al. Cytotoxic activity of polyacetylene compounds in Panax 
ginseng C. A. Meyer. Chem. Pharm. Bull. (Tokyo). 38, 3480–2 (1990). 
93. Vuksan, V. et al. Similar postprandial glycemic reductions with escalation of dose 
and administration time of American ginseng in type 2 diabetes. Diabetes Care 23, 
1221–6 (2000). 
94. Effect of petroleum ether extract of Panax ginseng roots on proliferation and cell 
cycle progression of human renal cell carcinoma cells. doi:10.1038/emm.1998.7 
95. Purup, S., Larsen, E. & Christensen, L. P. Differential effects of falcarinol and 
related aliphatic C(17)-polyacetylenes on intestinal cell proliferation. J. Agric. Food 
Chem. 57, 8290–6 (2009). 
96. Young, J. F. et al. Biphasic Effect of Falcarinol on CaCo-2 Cell Proliferation, DNA 
Damage, and Apoptosis. J. Agric. Food Chem. 55, 618–623 (2007). 
97. Morten Kobæk-Larsen, *,†, Lars P. Christensen, ‡, Werner Vach, §, Jelmera 
Ritskes-Hoitinga, † and & Brandt‖, K. Inhibitory Effects of Feeding with Carrots or 
(−)-Falcarinol on Development of Azoxymethane-Induced Preneoplastic Lesions in 
the Rat Colon. (2005). doi:10.1021/JF048519S 
98. Matthew W. Bernart, 1 et al. Cytotoxic Falcarinol Oxylipins from Dendropanax 
arboreus. (1996). doi:10.1021/NP960224O 
99. Jiang, L.-P., Lu, Y., Nie, B.-M. & Chen, H.-Z. Antiproliferative effect of panaxynol 
on RASMCs via inhibition of ERK1/2 and CREB. Chem. Biol. Interact. 171, 348–
354 (2008). 
100. Solomon, L. et al. The dextran sulphate sodium (DSS) model of colitis: an overview. 
Comp. Clin. Path. 19, 235–239 (2010). 
113 
 
101. Rose, W. A., Sakamoto, K. & Leifer, C. A. Multifunctional role of dextran sulfate 
sodium for in vivo modeling of intestinal diseases. BMC Immunol. 13, 41 (2012). 
102. Chassaing, B., Aitken, J. D., Malleshappa, M. & Vijay-Kumar, M. Dextran sulfate 
sodium (DSS)-induced colitis in mice. Curr. Protoc. Immunol. 104, Unit 15.25. 
(2014). 
103. Perše, M. & Cerar, A. Dextran sodium sulphate colitis mouse model: Traps and 
tricks. J. Biomed. Biotechnol. 2012, 1–13 (2012). 
104. Peng Yu, A., Cabanilla, L. A., Qiong Wu, E., Mulani, P. M. & Chao, J. The costs of 
Crohn’s disease in the United States and other Western countries: a systematic 
review. Curr. Med. Res. Opin. 24, 319–328 (2008). 
105. COHEN, R. D. et al. Systematic review: the costs of ulcerative colitis in Western 
countries. Aliment. Pharmacol. Ther. 31, 693–707 (2010). 
106. Kaplan, G. G. The global burden of IBD: from 2015 to 2025. Nat. Rev. 
Gastroenterol. Hepatol. 12, 720–727 (2015). 
107. Park, K. T. & Bass, D. Inflammatory bowel disease-attributable costs and cost-
effective strategies in the United States: A review. Inflamm. Bowel Dis. 17, 1603–
1609 (2011). 
108. Molodecky, N. A. et al. Increasing Incidence and Prevalence of the Inflammatory 
Bowel Diseases With Time, Based on Systematic Review. Gastroenterology 142, 
46–54.e42 (2012). 
109. Roda, G., Jharap, B., Neeraj, N. & Colombel, J.-F. Loss of Response to Anti-TNFs: 
Definition, Epidemiology, and Management. Clin. Transl. Gastroenterol. 7, e135 
(2016). 
110. Hofseth, L. J. & Ying, L. Identifying and defusing weapons of mass inflammation 
in carcinogenesis. Biochim. Biophys. Acta - Rev. Cancer 1765, 74–84 (2006). 
111. Hofseth, L. J. & Wargovich, M. J. Inflammation, cancer, and targets of ginseng. J. 
Nutr. 137, 183S–185S (2007). 
112. Zidorn, C. et al. Polyacetylenes from the Apiaceae Vegetables Carrot, Celery, 
Fennel, Parsley, and Parsnip and Their Cytotoxic Activities. J. Agric. Food Chem. 
53, 2518–2523 (2005). 
113. Wang, C. N., Shiao, Y. J., Kuo, Y. H., Chen, C. C. & Lin, Y. L. Inducible nitric 
oxide synthase inhibitors from Saposhnikovia divaricata and Panax quinquefolium. 
Planta Med. 66, 644–647 (2000). 
114. Kobaek-Larsen, M. et al. Dietary polyacetylenes, falcarinol and falcarindiol, 
isolated from carrots prevents the formation of neoplastic lesions in the colon of 
azoxymethane-induced rats. Food Funct. 8, 964–974 (2017). 
114 
 
115. Yang, Z. et al. Panaxynol protects cortical neurons from ischemia-like injury by up-
regulation of HIF-1α expression and inhibition of apoptotic cascade. Chem. Biol. 
Interact. 183, 165–171 (2010). 
116. Nie, B. M. et al. Protective effect of panaxydol and panaxynol on sodium 
nitroprusside- induced apoptosis in cortical neurons. Chem. Biol. Interact. 160, 225–
231 (2006). 
117. Yuan, C.-S. et al. Effects of Panax quinquefolius L. on brainstem neuronal activities: 
Comparison between Wisconsin-cultivated and Illinois-cultivated roots. 
Phytomedicine 8, 178–183 (2001). 
118. Morteau, O. et al. Impaired mucosal defense to acute colonic injury in mice lacking 
cyclooxygenase-1 or cyclooxygenase-2. J. Clin. Invest. 105, 469–78 (2000). 
119. Dieleman et al. Chronic experimental colitis induced by dextran sulphate sodium 
(DSS) is characterized by Th1 and Th2 cytokines. Clin. Exp. Immunol. 114, 385–
391 (1998). 
120. SANDBORN, W. J., FEAGAN, B. G. & LICHTENSTEIN, G. R. Medical 
management of mild to moderate Crohn?s disease: evidence-based treatment 
algorithms for induction and maintenance of remission. Aliment. Pharmacol. Ther. 
26, 987–1003 (2007). 
121. Leonti, M. et al. Falcarinol is a covalent cannabinoid CB1 receptor antagonist and 
induces pro-allergic effects in skin. Biochem. Pharmacol. 79, 1815–1826 (2010). 
122. Qualls, J. E., Kaplan, A. M., van Rooijen, N. & Cohen, D. A. Suppression of 
experimental colitis by intestinal mononuclear phagocytes. J. Leukoc. Biol. 80, 802–
15 (2006). 
123. Xavier, R. J. & Podolsky, D. K. Unravelling the pathogenesis of inflammatory 
bowel disease. Nature 448, 427–434 (2007). 
124. Bader, J. E. et al. Macrophage depletion decreases inflammation and tumorigenesis 
in the AOM/DSS mouse model of colon cancer. J. Immunol. 196, (2016). 
125. Blonski, W. & Lichtenstein, G. R. Safety of biologic therapy. Inflamm. Bowel Dis. 
13, 769–796 (2007). 
126. Lichtenstein, G. R., Abreu, M. T., Cohen, R., Tremaine, W. & American 
Gastroenterological Association. American Gastroenterological Association 
Institute Technical Review on Corticosteroids, Immunomodulators, and Infliximab 
in Inflammatory Bowel Disease. Gastroenterology 130, 940–987 (2006). 
127. Domm, S., Cinatl, J. & Mrowietz, U. The impact of treatment with tumour necrosis 
factor-α antagonists on the course of chronic viral infections: a review of the 
literature. Br. J. Dermatol. 159, 1217–1228 (2008). 
128. Kruis, W. et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three 
115 
 
times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 
g twice daily) was superior in preventing relapses. Gut 49, 783–9 (2001). 
129. Hilsden, R. Complementary and alternative medicine use by Canadian patients with 
inflammatory bowel disease: results from a national survey. Am. J. Gastroenterol. 
98, 1563–1568 (2003). 
130. Head, K. A. & Jurenka, J. S. Inflammatory bowel disease Part 1: ulcerative colitis--
pathophysiology and conventional and alternative treatment options. Altern. Med. 
Rev. 8, 247–83 (2003). 
131. Sartor, R. B. Mechanisms of Disease: pathogenesis of Crohn’s disease and 
ulcerative colitis. Nat. Clin. Pract. Gastroenterol. Hepatol. 3, 390–407 (2006). 
132. Tanida, S. et al. Involvement of oxidative stress and mucosal addressin cell adhesion 
molecule-1 (MAdCAM-1) in inflammatory bowel disease. J. Clin. Biochem. Nutr. 
48, 112–116 (2011). 
133. Pravda, J. Radical induction theory of ulcerative colitis. World J. Gastroenterol. 11, 
2371–84 (2005). 
134. Pavlick, K. P. et al. Role of reactive metabolites of oxygen and nitrogen in 
inflammatory bowel disease. Free Radic. Biol. Med. 33, 311–22 (2002). 
135. Esworthy, R. S. et al. Mice with combined disruption of Gpx1 and Gpx2 genes have 
colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 281, G848-55 (2001). 
136. Watterlot, L. et al. Intragastric administration of a superoxide dismutase-producing 
recombinant Lactobacillus casei BL23 strain attenuates DSS colitis in mice. Int. J. 
Food Microbiol. 144, 35–41 (2010). 
137. Oku, T. et al. Amelioration of murine dextran sulfate sodium-induced colitis by ex 
vivo extracellular superoxide dismutase gene transfer. Inflamm. Bowel Dis. 12, 630–
40 (2006). 
138. Kruidenier, L. et al. Attenuated mild colonic inflammation and improved survival 
from severe DSS-colitis of transgenic Cu/Zn-SOD mice. Free Radic. Biol. Med. 34, 
753–65 (2003). 
139. Li, J., Ichikawa, T., Janicki, J. S. & Cui, T. Targeting the Nrf2 pathway against 
cardiovascular disease. Expert Opin. Ther. Targets 13, 785–94 (2009). 
140. Magesh, S., Chen, Y. & Hu, L. Small Molecule Modulators of Keap1-Nrf2-ARE 
Pathway as Potential Preventive and Therapeutic Agents. Med. Res. Rev. 32, 687–
726 (2012). 
141. Taguchi, K., Motohashi, H. & Yamamoto, M. Molecular mechanisms of the Keap1-
Nrf2 pathway in stress response and cancer evolution. Genes to Cells 16, 123–140 
(2011). 
116 
 
142. Li, W. & Kong, A.-N. Molecular mechanisms of Nrf2-mediated antioxidant 
response. Mol. Carcinog. 48, 91–104 (2009). 
143. Katsuragi, Y., Ichimura, Y. & Komatsu, M. Regulation of the Keap1–Nrf2 pathway 
by p62/SQSTM1. Curr. Opin. Toxicol. 1, 54–61 (2016). 
144. Eggler, A. L., Liu, G., Pezzuto, J. M., van Breemen, R. B. & Mesecar, A. D. 
Modifying specific cysteines of the electrophile-sensing human Keap1 protein is 
insufficient to disrupt binding to the Nrf2 domain Neh2. Proc. Natl. Acad. Sci. U. S. 
A. 102, 10070–5 (2005). 
145. Zhu, H. & Li, Y. R. Oxidative stress and redox signaling mechanisms of 
inflammatory bowel disease: updated experimental and clinical evidence. Exp. Biol. 
Med. 237, 474–480 (2012). 
146. Shepela, C. The safety of biologic agents in the treatment of inflammatory bowel 
disease. Minn. Med. 91, 42–5 (2008). 
147. Khor, T. O. et al. Increased susceptibility of Nrf2 knockout mice to colitis-
associated colorectal cancer. Cancer Prev. Res. (Phila). 1, 187–91 (2008). 
148. Khor, T. O. et al. Nrf2-deficient mice have an increased susceptibility to dextran 
sulfate sodium-induced colitis. Cancer Res. 66, 11580–4 (2006). 
149. Bak, M. J. et al. Induction of Nrf2/ARE-mediated cytoprotective genes by red 
ginseng oil through ASK1-MKK4/7-JNK and p38 MAPK signaling pathways in 
HepG2 cells. J. Ginseng Res. 40, 423–430 (2016). 
150. Saw, C. L.-L., Wu, Q. & Kong, A.-N. T. Anti-cancer and potential chemopreventive 
actions of ginseng by activating Nrf2 (NFE2L2) anti-oxidative stress/anti-
inflammatory pathways. Chin. Med. 5, 37 (2010). 
151. Park, S.-H., Jang, J.-H., Chen, C.-Y., Na, H.-K. & Surh, Y.-J. A formulated red 
ginseng extract rescues PC12 cells from PCB-induced oxidative cell death through 
Nrf2-mediated upregulation of heme oxygenase-1 and glutamate cysteine ligase. 
Toxicology 278, 131–9 (2010). 
152. Ramesh, T. et al. Effect of fermented Panax ginseng extract (GINST) on oxidative 
stress and antioxidant activities in major organs of aged rats. Exp. Gerontol. 47, 77–
84 (2012). 
153. Puzio-Kuter, A. M. The Role of p53 in Metabolic Regulation. Genes Cancer 2, 385–
91 (2011). 
154. Budanov, A. V. The role of tumor suppressor p53 in the antioxidant defense and 
metabolism. Subcell. Biochem. 85, 337–58 (2014). 
155. Kobayashi, E. H. et al. Nrf2 suppresses macrophage inflammatory response by 
blocking proinflammatory cytokine transcription. Nat. Commun. (2016). 
doi:10.1038/ncomms11624 
117 
 
156. Cheng, X., Ku, C.-H. & Siow, R. C. M. Regulation of the Nrf2 antioxidant pathway 
by microRNAs: New players in micromanaging redox homeostasis. Free Radic. 
Biol. Med. 64, 4–11 (2013). 
157. Osburn, W. O. et al. Increased colonic inflammatory injury and formation of 
aberrant crypt foci in Nrf2-deficient mice upon dextran sulfate treatment. Int. J. 
Cancer 121, 1883–1891 (2007). 
158. Arisawa, T. et al. Nrf2 gene promoter polymorphism is associated with ulcerative 
colitis in a Japanese population. Hepatogastroenterology. 55, 394–7 
159. Arisawa, T. et al. Nrf2 gene promoter polymorphism and gastric carcinogenesis. 
Hepatogastroenterology. 55, 750–4 
160. Schneider, K. S. & Chan, J. Y. Emerging role of Nrf2 in adipocytes and adipose 
biology. Adv. Nutr. 4, 62–6 (2013). 
161. Joshi, G. & Johnson, J. A. The Nrf2-ARE pathway: a valuable therapeutic target for 
the treatment of neurodegenerative diseases. Recent Pat. CNS Drug Discov. 7, 218–
29 (2012). 
162. Chapple, S. J., Siow, R. C. M. & Mann, G. E. Crosstalk between Nrf2 and the 
proteasome: therapeutic potential of Nrf2 inducers in vascular disease and aging. 
Int. J. Biochem. Cell Biol. 44, 1315–20 (2012). 
163. Wang, X. & Hai, C. X. ROS acts as a double-edged sword in the pathogenesis of 
type 2 diabetes mellitus: is Nrf2 a potential target for the treatment? Mini Rev. Med. 
Chem. 11, 1082–92 (2011). 
164. Yoo, K. M., Lee, C., Lo, Y. M. & Moon, B. The Hypoglycemic Effects of American 
Red Ginseng (Panax quinquefolius L.) on a Diabetic Mouse Model. J. Food Sci. 77, 
H147–H152 (2012). 
165. Kitts, D. D., Wijewickreme, A. N. & Hu, C. Antioxidant properties of a North 
American ginseng extract. Mol. Cell. Biochem. 203, 1–10 (2000). 
166. Kim, J.-H. et al. Effects of Korean red ginseng extract on cisplatin-induced nausea 
and vomiting. Arch. Pharm. Res. 28, 680–684 (2005). 
167. Barton, D. L. et al. Wisconsin Ginseng (Panax quinquefolius) to improve cancer-
related fatigue: a randomized, double-blind trial, N07C2. J. Natl. Cancer Inst. 105, 
1230–8 (2013). 
168. Mehendale, S. et al. American ginseng berry extract and ginsenoside Re attenuate 
cisplatin-induced kaolin intake in rats. Cancer Chemother. Pharmacol. 56, 63–69 
(2005). 
169. Lydyard PM, Whelan A, F. M. BIOS Instant Notes in Immunology - Peter Lydyard, 
Alex Whelan, Michael Fanger - Google Books. (2000). 
118 
 
170. The immune system: recognition of infectious agents. Anaesth. Intensive Care Med. 
7, 179–180 (2006). 
171. Akira, S. & Takeda, K. Toll-like receptor signalling. Nat. Rev. Immunol. 4, 499–511 
(2004). 
172. Akira, S., Takeda, K. & Kaisho, T. Toll-like receptors: critical proteins linking 
innate and acquired immunity. Nat. Immunol. 2, 675–680 (2001). 
173. Drexler, S. K. & Foxwell, B. M. The role of Toll-like receptors in chronic 
inflammation. Int. J. Biochem. Cell Biol. 42, 506–518 (2010). 
174. Joosten, L. A. B., Abdollahi-Roodsaz, S., Dinarello, C. A., O’Neill, L. & Netea, M. 
G. Toll-like receptors and chronic inflammation in rheumatic diseases: new 
developments. Nat. Rev. Rheumatol. 12, 344–357 (2016). 
175. Shcheblyakov, D. V et al. Toll-Like Receptors (TLRs): The Role in Tumor 
Progression. Acta Naturae 2, 21–9 (2010). 
176. Mosser, D. M. & Edwards, J. P. Exploring the full spectrum of macrophage 
activation. Nat. Rev. Immunol. 8, 958–69 (2008). 
177. Gallego, C., Golenbock, D., Gomez, M. A. & Saravia, N. G. Toll-like receptors 
participate in macrophage activation and intracellular control of Leishmania 
(Viannia) panamensis. Infect. Immun. 79, 2871–9 (2011). 
178. Li, Q. & Cherayil, B. J. Role of Toll-like receptor 4 in macrophage activation and 
tolerance during Salmonella enterica serovar Typhimurium infection. Infect. Immun. 
71, 4873–82 (2003). 
179. Laskin, D. L., Sunil, V. R., Gardner, C. R. & Laskin, J. D. Macrophages and tissue 
injury: agents of defense or destruction? Annu. Rev. Pharmacol. Toxicol. 51, 267–
88 (2011). 
180. Ghochikyan, A. et al. Targeting TLR-4 with a novel pharmaceutical grade plant 
derived agonist, Immunomax®, as a therapeutic strategy for metastatic breast 
cancer. J. Transl. Med. 12, 322 (2014). 
181. Lai, C.-Y., Su, Y.-W., Lin, K.-I., Hsu, L.-C. & Chuang, T.-H. Natural Modulators 
of Endosomal Toll-Like Receptor-Mediated Psoriatic Skin Inflammation. J. 
Immunol. Res. 2017, 1–15 (2017). 
182. Peri, F. & Calabrese, V. Toll-like receptor 4 (TLR4) modulation by synthetic and 
natural compounds: an update. J. Med. Chem. 57, 3612–22 (2014). 
183. Chahal, D. S., Sivamani, R. K., Isseroff, R. R. & Dasu, M. R. Plant-Based 
Modulation of Toll-like Receptors: An Emerging Therapeutic Model. Phyther. Res. 
27, n/a-n/a (2013). 
184. Troutman, T. D., Bazan, J. F. & Pasare, C. Toll-like receptors, signaling adapters 
119 
 
and regulation of the pro-inflammatory response by PI3K. Cell Cycle 11, 3559–67 
(2012). 
185. Steinhagen, F., Kinjo, T., Bode, C. & Klinman, D. M. TLR-based immune 
adjuvants. Vaccine 29, 3341–3355 (2011). 
186. Gnjatic, S., Sawhney, N. B. & Bhardwaj, N. Toll-like receptor agonists: are they 
good adjuvants? Cancer J. 16, 382–91 (2010). 
187. Temizoz, B., Kuroda, E. & Ishii, K. J. Vaccine adjuvants as potential cancer 
immunotherapeutics. Int. Immunol. 28, 329–38 (2016). 
188. Cluff, C. W. in Advances in experimental medicine and biology 667, 111–123 
(2009).
120 
 
APPENDIX A.  
 
EPIGENETIC EFFECTS OF AMERICAN GINSENG AND ITS 
COMPONENTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.1 AG, HAG, and Panaxynol decrease the expression of DNMT-1 and 
HDAC1 in stimulated ANA-1 cells. ANA-1 cells were pretreated with AG (250 µg/ml), 
HAG (10 µg/ml), or Panaxynol (5 µM), followed by stimulation with IFN-γ (10 ng/ml) for 
indicated times.  
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